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ABSTRACT 
 
Growth and proliferation are normal functions of cells mediated in part via receptor tyrosine 
kinases such as the epidermal growth factor (EGF) receptor (EGFR).  The EGFR binds the 
extracellular signaling ligand EGF and transduces the signal into the cell.  Phosphatidylinositol 
3'-kinase (PI3K) responds to EGFR activation and initiates downstream signaling cascades 
responsible for cell cycle entry, proliferation and inhibition of apoptosis.  Cell cycle arrest is 
required to stop cell growth and proliferation as well as allow apoptosis, if required.  The 
phosphatase and tensin homologue deleted on chromosome ten (PTEN) directly opposes PI3K 
signaling since its substrate is the PI3K product phosphatidylinositol 3,4,5-trisphosphate.  PI3K 
is a heterodimer composed of a p85 regulatory subunit and a p110 catalytic subunit.  PTEN is an 
essential tumor suppressor protein.  Absence of PTEN has been associated with several types of 
cancer.   
Our laboratory has characterized new specialized functions for the p85 protein.  One function 
discovered was the ability of p85 to enhance PTEN lipid phosphatase activity.  In this thesis 
PTEN activity is shown to be enhanced at least 3.5 fold in vitro by an equimolar amount of p85.  
We performed an analysis of PTEN using seven PTEN mutants.  Two types of mutants were 
created: i) regulatory or possible regulatory phosphorylation sites were substituted to mimic both 
phosphorylated and non-phosphorylated states and ii) alanine substitution of basic amino acid 
residues.  The phosphorylation sites altered were the casein kinase 2 phosphorylation sites in the 
regulatory domain and tyrosine 336, a proposed regulatory phosphorylation site.  Three mutants 
involving alanine substitution for basic amino acid residues included one mutant in the PASE 
domain and two more mutants in the C2 domain.  It was observed that GFP-PTEN translocates 
to the plasma membrane upon EGF stimulation.  The mimic of constitutive phosphorylation of 
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the Casein kinase 2 sites resulted in cytoplasmic localization whereas the non-phosphorylated 
mimic was plasma membrane localized regardless of EGFR activation status.  Neutralization of 
positive charge in the PASE and C2 domains seriously impeded the ability of PTEN to bind to 
phosphorylated phosphatidylinositol lipids and abolished the ability of the protein to translocate 
to the plasma membrane in response to receptor activation.  Located within a cluster of positively 
charged lysine residues in the C2 domain is a potential phosphorylation site at tyrosine 336.  The 
phosphorylation mimic showed decreased binding to some membrane lipids compared to the 
non-phosphorylated mimic. 
The results we generated are consistent with a current model for PTEN regulation that 
proposes PTEN is localized to the cytoplasm in quiescent cells and dephosphorylation of the 
regulatory domain occurs upon EGF stimulation allowing translocation to the plasma membrane.  
The model proposes that dephosphorylation of the casein kinase 2 sites unmasks regions of 
positive charge that interact with the anionic plasma membrane.  Furthermore, the results 
suggested that at the plasma membrane p85 interacts with PTEN to increase lipid phosphatase 
activity and may be involved in targeting PTEN to the activated receptor where PI3,4,5P3 lipids 
are being produced. 
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1.0 INTRODUCTION 
1.1 Signal Transduction 
 
In order for any multicellular organism to function there needs to be mechanisms to control 
the array of individual cells in relation to the organism as a whole.  Specialized cell types have 
evolved with unique structural characteristics and functions.  In order for these cells to 
effectively carry out the functions required of them, a communication network is required.  
Through this network the organism as a whole is able to mediate the function and behavior of the 
individual cells.  The signals sent through the network are numerous and include messages to 
regulate differentiation, proliferation and cell death (apoptosis).  Each cell is, by definition, a 
functional unit isolated by the presence of a semi-permeable lipid bilayer called the plasma 
membrane.  Although some signaling molecules, such as small chemicals and drugs, are capable 
of traversing the plasma membrane, many cannot (Schuller, 1991).  In some instances, signal 
factors activate lipid-gated transmembrane ion channels allowing entrance or exit of specific 
ions, which allows regulation of cellular function (Gready et al., 1997).  Some signaling 
molecules require a receptor located on the cell surface that spans the intermembrane space to 
convey information about the extracellular environment (Gururaj and Kumar, 2005; Schuller, 
1991).  The event of an extracellular signaling molecule binding a cell surface receptor results in 
a conformational change to the cytoplasmic portion of the receptor.  Thus the signaling molecule 
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itself remains extracellular while the essence of the message is transferred, or transduced, inside 
the cell.  The integration, execution and attenuation of the signal inside the cell occurs via a 
cascade of second messengers involving various molecular interactions (Kolch, 2000).   
Important signaling biomolecules are produced by an assortment of sources and delivered by 
various processes.  These biomolecules may originate from adjacent cells, distant organs or even 
the external environment.  Signaling molecules that do not diffuse through the cell membrane 
include polypeptide growth factors, hormones, neuropeptides, neurotransmitters, the surfaces of 
neighboring cells, cytokines and the molecules of the extracellular matrix (Schuller, 1991).  
There are a plethora of signaling molecules involved in regulating the behavior and function of 
individual cells (Gururaj and Kumar, 2005).  Correspondingly there is diverse set of receptors 
that bind these signaling molecules and transduce specific signals (Gururaj and Kumar, 2005).  
Specific cell types are in part defined by the types of receptors they express.  How, or even if, a 
cell responds to a particular external stimulus is dictated in part by the particular receptors it 
expresses.  Once a signal is received by a receptor, transduction occurs via a change in activation 
status and/or localization of a variety of cytoplasmic enzymes (Yu et al., 1998).  The signal is 
often amplified as one receptor may activate several enzymes and each enzyme acts on several 
substrate molecules that act as second messengers.  The set of molecules involved in 
transduction and amplification of the signal are of varying size and composition and include 
small lipids, short peptides, proteins and large macromolecular multi-protein complexes.  The 
signaling proteins found in cells are often conserved, but the specific responses and modulation 
of the signal may vary with cell type. 
The interactions between molecules are often reversible and are tightly controlled.  Regulation 
usually involves negative feedback loops that are initiated via the transduction of the original 
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signal.  Multiple levels of regulation exist to ensure that the initial signal is not an exaggerated or 
insufficient response to the desired signal (Yu et al., 2003).  
Loss of function or total loss of proteins involved in signal transduction pathways are 
implicated in the pathophysiology of many diseases, including cancers (Yu et al., 2003).  
Regulatory abnormalities are often caused by mutations or total deletion of genes that encode 
signal transduction proteins.  Regulation of signal transduction molecules may involve a wide 
range of posttranslational modifications including the addition of functional groups such as 
lipids, methyls, ubiquitin, sugars, acetyls or phosphate groups.  Hydrolytic cleavage at specific 
sites or total proteolytic degradation may also be incorporated in the regulation of signaling.  
With regard to signal transduction, the most utilized and best studied form of regulation is the 
addition and removal of phosphate groups to free hydroxyls by kinases and phosphatases, 
respectively.       
 
1.2 Receptor Tyrosine Kinases 
 
In order for a signal such as a hormone or growth factor to exert its effect on a cell, it must 
bind its specific receptor on the cell surface.  One such family of cell receptors has intrinsic 
kinase activity and these receptors utilize ATP to transfer the γ phosphate group to the hydroxyl 
of a tyrosine amino acid residue (Adamson and Rees, 1981).  This group of cell signaling 
receptors is collectively termed receptor tyrosine kinases (RTKs).  According to current 
databases (IUPHAR) there are twenty classifications of RTKs that have been identified to date 
(Vanhoutte, 2006).  Receptors are typically very large proteins possessing a transmembrane 
domain that allows the protein to span the plasma membrane and thus transduce the extracellular 
signal by causing changes inside the cell. The changes induced by RTK signaling are widespread 
and can include processes such as differentiation, altered metabolism, proliferation or cell 
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survival (Simon, 2000).  Also, an RTK signal in one cell type may have an entirely different 
function in another cell type.  This is especially true with regard to undifferentiated cells, such as 
fibroblasts, versus fully differentiated cells, such as epithelia (Halfon et al., 2000).    
Upon ligand binding, RTKs are activated by dimerization of subunits, which results in 
autophosphorylation of tyrosine residues within the cytoplasmic domains (Pandey et al., 1994).  
Many RTK types include multiple isoforms, so dimerization may include homodimerization or 
heterodimerization (Pandey et al., 1994).  Phosphorylation of the cytoplasmic tyrosine residues 
results, in some cases, in the recruitment of signaling molecules to the receptor.  Typically, 
translocation to the receptor positions RTK binding proteins in proximity to their substrate and 
may also increase their activity, which results in the initiation of various downstream cascades.  
The duration a ligand binds to its receptor is variable and some signals have quite a long duration 
whereas others, such as growth factor signaling, are very transient (Marshall, 1995).  A common 
thread between all types of RTKs is that through transduction of the original signal, transcription 
factors are activated or inactivated, either directly or indirectly, to activate or repress 
transcription of specific genes (Simon, 2000).  In normal cells, regardless of function, specific 
patterns of proliferation are adhered to (George, 2003).  Strict control of these patterns is partly 
controlled by RTK signaling pathways that transduce extracellular information into intracellular 
signals (George, 2003).  Normal cells rely on efficient and tightly controlled RTK signaling to 
carry out their normal physiological roles including metabolism, growth and proliferation 
(George, 2003).  Mutations in RTKs, or components of the signaling pathways they regulate, can 
drive unregulated cell growth and may repress the ability undergo apoptosis (Nam and Parang, 
2003).  RTKs and downstream signaling proteins in those pathways are often deregulated in 
cancer cells due to their inherent ability to promote proliferative signaling. 
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The epidermal growth factor (EGF) receptor (EGFR) is a well studied subclass of RTK that 
has been associated with human cancers (Stoscheck and King, 1986).  EGFRs consist of a 
cytoplasmic protein tyrosine kinase domain, a transmembrane domain and extracellular ligand 
binding domain containing several α-solenoid or β-helix folds (Jorissen et al., 2003) (Figure 1.1).  
Humans have four subclasses of EGFR that have been classified types 1-4 (Navolanic et al., 
2003).  Type 1 is the EGFR/Her1 receptor and types 2-4 are classified Her2, Her3 and Her4 
(George, 2003).  The four subclasses of EGFR are capable of homodimerization (Olayioye et al., 
2000).  As well, types 1, 3 and 4 are capable of heterodimerization with type 2 (Figure 1.2 a) 
(Olayioye et al., 2000).  There are also two main classes of EGF ligand, EGF and neuregulin 
(NRG) (Navolanic et al., 2003).  The EGF ligand family includes: EGF, heparin binding EGF 
(HB-EGF), transforming growth factor α (TGFα), β cellulin, amphiregulin and epiregulin 
(Navolanic et al., 2003).  The NRG ligand family consists of NRG α, NRG β, NRG 2α, NRG 2β, 
NRG 3α and NRG 3β.  Hetero- and homodimerization of the receptor classes combined with the 
two classes of EGF ligand provides a fairly high degree of specificity regarding signal  type  
(Burgess et al., 2003; Jorissen et al., 2003; Navolanic et al., 2003).  Not every type of EGF 
ligand binds every receptor combination (Figure 1.2 b) (Olayioye et al., 2000).  The EGFR only 
binds EGF family ligands (Olayioye et al., 2000).  However, β cellulin, HB-EGF and epiregulin 
also bind Her4 (Olayioye et al., 2000).  The NRG ligand family does not bind the EGFR, but 
does bind the Her3 and Her4 receptors (Olayioye et al., 2000). 
Upon EGF binding, the EGFR homodimerizes and undergoes autophosphorylation of several 
tyrosines located within the cytosolic portion of the receptor (Earp et al., 1995; Moriki et al., 
2001).  Phosphorylation of these cytosolic tyrosine residues creates docking sites for proteins 
that contain the appropriate recognition domain (Pawson et al., 2001).  Several proteins are 
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Figure 1.1: Domain structure of the EGFR and schematic including some EGFR binding 
proteins.  The EGFR contains several cytosolic tyrosine residues, a protein tyrosine kinase 
domain, a transmembrane domain and an extracellular ligand binding domain.  Proteins that 
contain SH2 domains such as Grb2, p85 and SHP1, bind to the phosphotyrosines of the EGFR in 
response to ligand binding. 
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(a)
(b)
 
Figure 1.2: Heterodimerization of EGFR isoforms and binding preference of EGF and 
EGF-like ligands.  (a) Her2 itself does not homodimerize but heterodimerizes with EGFR (1), 
Her3 (3) and Her4 (4).  Her3 is capable of homodimerization, but has no associated signaling (x).  
Her4 is capable of homo- and heterodimerization.  (b) schematic of EGF ligands and their 
receptors.  EGFR (1) binds the EGF ligand family, EGF, TGFα, amphiregulin, β-cellulin, HB-
EGF and epiregulin, but not the NRG ligand family. β-cellulin, HB-EGF and epiregulin all bind 
Her4 as well as EGFR.  The NRG ligand family does not bind the EGFR. Modified from 
Olayioye (2000).  
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capable of interacting with these phosphotyrosines either via src homology 2 (SH2) domains or 
phosphotyrosine binding (PTB) domains (Jones and Dumont, 1999; Ricketts et al., 1996).  The 
difference in binding specificity between SH2 and PTB domains is that SH2 domains bind motifs 
that extend C terminal from a phosphotyrosine (e.g. pYXXM, where pY is a phosphotyrosine, X 
is any amino acid and M is methionine) whereas PTB domains bind motifs that extend amino 
terminal from a phosphotyrosine (NPXpY) (Navolanic et al., 2003).  An abundant amount of 
proteins containing SH2 and/or PTB domains are capable of binding phosphorylated EGFR of 
which only a selected few are shown (Figure 1.1). 
Reversal or attenuation of RTK signaling is essential for effective transduction of the signal as 
hyperactivity of these cascades leads to uncontrolled cell growth.  Activated RTKs lead to 
expression and activation of proteins that promote cell cycle progression and apoptotic inhibition 
(Navolanic et al., 2003).  Overexpression of EGFR results in dimerization and 
autophosphorylation in the absence of ligand, which also leads to cell transformation due to 
over-activity of pathways that promote cell survival and cell cycle progression (Chazin et al., 
1992; Di Fiore et al., 1987).  The simplest biochemical mechanism of attenuation is the removal 
of the phosphate group from the tyrosine by protein tyrosine phosphatases that contain SH2 
domains, such as SHP-1 (Ostman and Bohmer, 2001).  Another mechanism of opposing 
downstream signaling is through serine phosphorylation to disrupt the effect of the 
phosphotyrosines (Jorissen et al., 2003).  Additionally the entire receptor and ligand complex 
may be endocytosed and targeted for degradation (Sweeney and Carraway, 2004).  Finally, fine 
tuning of the signal can be accomplished via protein interactions immediately downstream of the 
receptor.  
Two important pathways that mediate parallel EGFR signaling cascades are the Ras/Raf/ 
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mitogen activated protein kinase (MAPK) and phosphatidylinositol 3'-kinase (PI3K)/Akt 
pathways.  The Ras/Raf/MAPK pathway is a proliferation, differentiation and pro-survival 
signaling cascade that is ubiquitously utilized in many cell types and is evolutionarily conserved 
(Figure 1.3) (Kolch, 2002; Yuryev et al., 2000).  Ras is a guanine nucleotide binding protein 
constitutively localized to the plasma membrane due to a lipid anchor added posttranslationally 
(Bollag and McCormick, 1991).  Upon growth factor binding and receptor autophosphorylation, 
the PTB domain containing protein Shc is recruited to the receptor and phosphorylated on 
Tyr317 (van der Geer and Pawson, 1995).  This creates a docking site for the SH2 domain-
containing protein growth factor receptor-bound protein 2 (Grb2), which may alternatively bind 
directly to the activated receptor as shown in figure 1.1 (Heldin et al., 1998).  Grb2 functions as 
an adapter protein that localizes the guanine nucleotide exchange protein, son of sevenless 
(SOS), to the plasma membrane (Campbell et al., 1998).  At the plasma membrane, SOS 
mediates the exchange of Ras-bound GDP for GTP (Lodish, 1995).  The conformational change 
induced by the change to Ras-GTP results in high-affinity binding to the Raf family of 
serine/threonine kinases.  Raf proteins are cytosolic in quiescent cells, but are targeted to the 
plasma membrane by direct interaction with Ras-GTP (Avruch et al., 1994).  Raf becomes 
activated at the membrane and stimulates the dual specificity kinases MAPK/extracellular signal-
regulated kinase (ERK) kinases (MEK) 1 and 2 by serine phosphorylation (Schubbert et al., 
2007).  MEK phosphorylates MAPK on both a threonine and a tyrosine residue (Fukuhara et al., 
2000).  Phosphorylated MAPK is activated, translocates to the nucleus and upregulates various 
transcription factors, involved in cell growth and proliferation through phosphorylation (Cyert, 
2001).  
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Figure 1.3:  The Ras/Raf/MAPK signal transduction pathway.  Binding of EGF to the EGFR 
results in dimerization and autophosphorylation of tyrosine residues creating docking sites for 
PTB and SH2 domains such as Shc.  Phosphorylation of the adapter protein Shc recruits the 
Grb2/SOS complex.  SOS stimulates the exchange of Ras-bound GDP for GTP, which permits 
binding of Raf.  After binding to Ras, Raf phosphorylates MEK, which in turn phosphorylates 
and activates MAPK.  MAPK translocates to the nucleus and activates transcription factors via 
phosphorylation.  The transcription factors activated by MAPK are involved in cellular responses 
such as proliferation.  Note that this is a simplified representation of the Ras/Raf/MAPK 
pathway.  TF = transcription factor. 
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1.3 PI3K/Akt Signaling Pathway 
 
The PI3K/Akt pathway is a well-studied signaling cascade parallel to the Ras/Raf/MAP 
pathway.  PI3K/Akt signaling is activated when EGF binds to its receptor located on the cell 
surface.  This event results in autophosphorylation of the receptor and recruitment of PI3K to the 
receptor (Figure 1.1) (Cantley, 2002; Lo and Hung, 2006).  Although three classes of PI3Ks exist 
in higher eukaryotes, it is the class I enzymes that respond to growth factor stimulation and carry 
out phosphorylation of D-3 phosphoinositides (Cantley, 2002).  Class I PI3K are heterodimers 
composed of an 85 kDa regulatory subunit (p85) and a 110 kDa catalytic subunit (p110) 
(Cantley, 2002).  Three genes encode for the p85 protein, Pik3r1, Pik3r2 and Pik3r3 (Fruman et 
al., 1998).  Three isoforms are encoded by the Pik3r1 gene: p85α, p55α and p50α (Figure 1.4) 
(Fruman et al., 1998).  Isoforms p85β and p55γ are encoded by separate genes Pik3r2 and 
Pik3r3, respectively (Fruman et al., 1998).  The p85α isoform is the more abundant form of p85 
and henceforth p85α will be referred to as p85. All five isoforms contain two SH2 domains, 
which form stable complexes with phosphotyrosine sites present on activated EGFRs (McGlade, 
1992).  SH2 domains bind the consensus sequence of pYXXM (Funaki et al., 2000).  All five 
isoforms also have an inter-SH2 region that spans 200 amino acid residues (Klippel et al., 1993).  
The full-length p85 protein contains an N-terminal Src homology 3 (SH3) domain, which 
mediates binding to the proline-rich consensus sequence XPpXP (where P is always a proline 
and p is often a proline residue) (Klippel et al., 1993).  The break point cluster region (BCR) 
gene was originally identified as being involved in the translocation of chromosome 22 in 
chronic myelocytic leukemia patients (Heisterkamp et al., 1985).  Later, the product of the BCR 
gene was determined to be a Rho GTPase activating protein (GAP) (Ridley et al., 1993).  A BCR 
homology (BH) domain was discovered in p85 (Funaki et al., 2000) and it has been  
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Figure 1.4:  Domain structure of p85 and p110.  The p85 protein has two full length isoforms, 
α and β, as well as three smaller isoforms p55 α and β as well as p50.  Full length p85 has an 
SH3 domain, two proline-rich regions, BH domain, N-SH2 domain, p110 binding domain and C-
SH2 domain.  The smaller p85 isoforms are lacking the SH3 and BH domains.  The p110 protein 
is the catalytic subunit of PI3K and has a p85 binding domain and a kinase domain.  Adapted 
from Funaki et al., (2000). 
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demonstrated that p85 has GAP activity (Chamberlain et al., 2004). 
The catalytic activity of PI3K is carried out by the p110 subunit, which adds a phosphate 
group to the plasma membrane lipid component phosphatidylinositol 4,5 bisphosphate (PI4,5P2) 
at the D3 position of the inositol ring creating the product phosphatidylinositol 3,4,5-
trisphosphate (PI3,4,5P3) (Sulis and Parsons, 2003).  Four separate genes, Pik3CA, Pik3CB, 
Pik3CD and Pik3CG encode for four isoforms of p110: p110α, p110β, p110δ and p110γ (Funaki 
et al., 2000).  The delta (δ) isoform of p110 has not been shown to bind p85 (Foukas et al., 
2004).  Since the p85:p110 interaction is quite strong, this suggests specialized functions for the 
delta isoform (Foukas et al., 2004). The gamma (γ) isoform is expressed predominantly in 
leukocytes, suggesting a unique role for p110 in this cell type  (Foukas et al., 2004; Funaki et al., 
2000).  Henceforth p110α will be referred to as p110, since it is the isoform that pertains to this 
body of work.  The p110 protein consists of an N-terminal p85 binding domain and a C-terminal 
lipid kinase domain (Figure 1.4) (Klippel et al., 1994).  
The p85:p110 interaction controls three key functions for the PI3K heterodimer. The p85 
protein stabilizes p110, regulates enzymatic function and acts as an adapter protein to position 
p110 at the cell membrane in proximity to its lipid substrate (Cuevas et al., 2001; Foukas et al., 
2004; Klippel et al., 1994; Klippel et al., 1996).  The p110 protein is not stable at biological 
temperatures in the absence of p85.  The p85:p110 interaction is very stable and no dissociation 
has been observed (Yu et al., 1998).  The enzymatic activity of p110 has been shown to be 
constitutively active (at lower temperatures than biologically relevant), but p85 inhibits this 
activity (Yu et al., 1998).  Finally, p110 does not contain any SH2 or PTB domains, so its 
localization to the plasma membrane where its substrate is located is a function of p85 (Klippel 
et al., 1996).  The p85 protein has two SH2 domains that have been shown to bind activated 
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RTKs, such as the EGFR.   Upon the SH2 domains binding to the EGFR, the inhibition of 
p110/PI3K activity by p85 is relieved (Funaki et al., 2000).  Thus, in response to activation of 
the EGFR, the p85:p110 complex relocalizes to the plasma membrane and inhibition of PI3K 
activity is relieved.    
Investigation of the enzymatic activity of p110 revealed that it is a dual specificity kinase 
possessing 3' phosphoinositide activity as well as protein serine kinase activity (Stephens et al., 
1993).  It is the conversion of PI4,5P2 to PI3,4,5P3 that is the most biologically relevant activity 
with regard to the PI3K/Akt pathway, but the protein serine kinase activity, which 
autophosphorylates p85 at Ser608 may also be important for regulation of the PI3K enzyme 
(Dhand et al., 1994; Stephens et al., 1993).  Ser608 on p85 was identified as a regulatory 
phosphorylation site for PI3K (Foukas et al., 2004).  Foukas and colleagues demonstrated that it 
is the p110 subunit that catalyzes this reaction in response to activation of other RTKs such as 
the platelet derived growth factor receptor as well as the insulin-like growth factor receptor 
(Foukas et al., 2004).  The kinetics of Ser608 phosphorylation are slow in response to RTK 
activation, suggesting that inhibition of a phosphatase(s) occurs (Foukas et al., 2004).  
Furthermore, when cells are treated with the protein serine/threonine phosphatase inhibitor 
okadaic acid, the cellular levels of Ser608-phosphorylated p85 (pSer608-p85) increase (Foukas 
et al., 2004).  Yu and colleagues clearly demonstrated that p85 binding to p110 was sufficient for 
inhibition of PI3K lipid phosphatase activity regardless of Ser608 phosphorylation status (Yu et 
al., 1998).  Ser608 phosphorylation may be involved in a negative feedback mechanism to 
switch off PI3K activity.  It has been demonstrated that when the p85 SH2 domains bind 
phosphotyrosines, the lipid kinase activity of PI3K is activated (Carpenter et al., 1993).  Thus, in 
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the cytoplasm it is possible that a phosphatase removes the Ser608 phosphate.  Upon receptor 
activation, the Ser608 phosphatase is either inhibited or simply remains cytoplasmic and no 
longer has access to its p85 substrate, which has translocated to the plasma membrane.  At the 
plasma membrane, the SH2 domains of p85 bind the phosphorylated tyrosine residues and a 
conformational change activates p110 activity.  The p110 protein phosphorylates its lipid 
substrate as well as the p85 protein on Ser608 to attenuate the signal (Figure 1.5 a).  
Another important PI3K regulatory phosphorylation site is Tyr688 on p85.  Tyr688 is 
phosphorylated by the Src-family kinases Lck and Abl in response to cytokine signaling (von 
Willebrand et al., 1998).  When p85 is phosphorylated at Tyr688 (pTyr688), the binding 
properties of the SH2 domains are altered (von Willebrand et al., 1998).  Cuevas et al. 
demonstrated that p85 phosphorylated on Tyr688 is associated with higher lipid kinase activity 
than the nonphosphorylated state (Cuevas et al., 2001).  Interestingly, the phosphatase identified 
for dephosphorylating p85 at Tyr688 was the SH2 containing tyrosine phosphatase 1 (SHP1) 
(Cuevas et al., 1999).  These authors proposed two models for PI3K regulation involving 
pTyr688 and activated RTKs (Cuevas et al., 2001).  Their first model was an intramolecular 
regulatory mechanism in which Tyr688 masks the SH2 domains and inhibits enzymatic activity 
and pTyr688 relieves inhibition.  The second model described an intermolecular interaction. 
When a PI3K molecule binds the active RTK, pTyr688 serves as a docking site for the SH2 
domains of a second PI3K molecule.  The second PI3K also becomes phosphorylated at Tyr688 
and serves as a docking site for a third PI3K molecule, etc., thus amplifying of the original signal 
being transduced (Cuevas et al., 2001).  Based on the other evidence in the literature that 
pTyr688 is not required for PI3K localization or activation (Carpenter et al., 1993), neither of the  
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Figure 1.5: Models of PI3K signaling in response to RTK and cytokine receptor activation.  
(a) In the cytosol PI3K is catalytically inactive.  Upon RTK activation PI3K translocates to the 
plasma membrane and is activated upon receptor binding.  (b) Cytokine receptor activation 
results in tyrosine phosphorylation of Src-family kinases.  PI3K is recruited to the Src-family 
kinase, which phosphorylates it at Tyr688 and activates enzymatic activity.  Cuevas et al. 
proposed that Tyr688 phosphorylation also provides an SH2 docking site for a second PI3K 
molecule, which gets Tyr688 phosphorylated providing a docking site for a third PI3K etc. 
(Cuevas et al., 2001).   
  17 
models concerning RTK signaling proposed by Cuevas et. al. are valid.  However, the Cuevas 
intermolecular model may have some validity with regard to cytokine signaling.  I propose an 
adaptation of their model with regard to PI3K involvement in cytokine signaling (Figure 1.5 b).  
Cytokine receptor activation results in tyrosine phosphorylation of Src family kinases.  PI3K is 
recruited to the membrane-localized Src family kinase and is phosphorylated at Tyr688.  As 
proposed by Cuevas and colleagues (2001), the pTyr688 may be a docking site for another PI3K, 
which is then phosphorylated on Tyr688 creating a docking site for another PI3K molecule, etc.   
Phosphatidylinositol (PI) constitutes only 10% of the total lipid content in eukaryotic cell 
membranes and thus has a minor role in the structure of the cell plasma membrane (Rameh and 
Cantley, 1999).  The inositol ring of PI contains five free hydroxyls with the potential to become 
phosphorylated by lipid kinases such as PI3K (Figure 1.6) (Fruman et al., 1998). PI is well 
recognized for its importance in cell signaling because it is the precursor to all phosphoinositide 
second messengers, such as PI3,4,5P3 (Rameh and Cantley, 1999).   
Upon phosphorylation of PI4,5P2 by PI3K, the product PI3,4,5P3  interacts with the PH 
domain containing-protein, phosphoinositide-dependent kinase-1 (PDK1) (Figure 1.7).  PDK1 is 
a serine/threonine kinase critical for Akt activation (Cohen et al., 1997).  Akt also has a PH 
domain and translocates to the plasma membrane in response to an increase in PI3,4,5P3 lipids 
(Kikani et al., 2005).  At the plasma membrane, Akt is phosphorylated by PDK1 at residue 
Thr308 in the activation loop (Anderson et al., 1998) and possibly at Ser473 as well (Song et al., 
2005, Ueki et al., 2002) (Figure 1.7).  Phosphorylation of Thr308 is not a prerequisite for Ser473 
phosphorylation or vice versa (Alessi et al., 1996).  However, phosphorylation of both residues  
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Figure 1.6:  Chemical structure of phosphatidylinositol.  Phosphatidylinositol (PI) is a plasma 
membrane lipid component.  PI is also important as it is the precursor to important lipid second 
messengers.  Note the free hydroxyls indicated at positions 2-6 of the inositol ring.  The 
phosphoinositides that have been characterized in mammalian cells are PI3P, PI4P, PI5P, 
PI3,4P2, PI3,5P2, PI4,5P2, and PI3,4,5P3.  PI4,5P2 is a substrate for PI3K, which adds a 
phosphate to the 3' hydroxyl to create PI3,4,5P3.  PI3,4,5P3 is a potent second messenger that 
recruits Akt to the plasma membrane initiating several proliferative and anti-apoptotic pathways.  
Phosphatase PTEN dephosphorylates PI3,4,5P3 at the 3' position. Arrows represent upregulation 
whereas squares denote downregulation or inhibition.  Adapted from Fruman et al. (1998). 
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Figure 1.7: Schematic diagram of the PI3K/Akt Signal Transduction Pathway.  Upon EGF 
binding to the EGFR, PI3K is recruited to the plasma membrane by the p85 subunit.  PI4,5P2 is 
phosphorylated by p110 at the D-3 position on the inositol ring, creating the product PI3,4,5P3.  
Tumor suppressor PTEN phosphatase catalyzes the reverse reaction. PI3,4,5P3 recruits PH 
domain containing proteins Akt and PDK1.  PDK1 phosphorylates Akt in the activation loop.  
Akt signaling inhibits apoptotic signals, initiates transcription and promotes cell proliferation.  
Note that this is a simplified schematic of the PI3K/Akt signal transduction pathway, with Akt 
targets described in more detail in a subsequent figure. 
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is required for high activation of Akt (Alessi et al., 1996).  Currently, some ambiguity exists 
regarding the kinase responsible for Ser473 phosphorylation.  Initially PDK1 was the kinase 
proposed to have this function, but other kinases may be involved, including: the integrin linked 
kinase (ILK), mTOR RICTOR, or even Akt itself (Hresko and Mueckler, 2005; Okamura et al., 
2007; Song et al., 2005).  Given that Akt is ubiquitously expressed, it stands to reason that it 
would have several activators that have tissue and/or signal specific activity.  Active Akt results 
in signaling cascades that have endpoints such as initiation of transcription and promotion of cell 
proliferation (Song et al., 2005). 
Although there are three isoforms of Akt, all consist of a conserved domain structure 
including an N-terminal PH domain, a C-terminal regulatory domain and a central 
serine/threonine kinase domain (Song et al., 2005).  Current models of Akt signaling include 
activation of eight distinct pathways involved in cell survival and proliferation (Figure 1.8).  Two 
pathways are involved in direct regulation of apoptosis, five more include transcriptional control 
of apoptosis, and one pathway involves metabolic regulation of apoptosis via glucose 
metabolism (Figure 1.8) (Song et al., 2005).   
One Akt target is the protein BAD, which is a member of the Bcl-2 family of proteins. BAD 
and Bcl-2-associated_x_protein (Bax) alternatively bind to Bcl-2 or its homolog Bcl-xL.  When 
BAD is bound to Bcl-2 or Bcl-xL, Bax localizes to the mitchondrial membrane resulting in the 
release of cytochrome c from the organelle (del Peso et al., 1997).  The release of cytochrome c 
from the mitochondria is a trigger of the apoptosome. When BAD is phosphorylated by Akt, it 
loses the ability to bind Bcl-2 or Bcl-xL, which results in the sequestering of Bax by these 
proteins and inhibition of apoptosis (Datta et al., 1999; Datta et al., 1997). 
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Figure 1.8:  Multiple mechanisms of cell survival regulation by Akt.  Upon receptor 
activation and autophosphorylation PI3K is recruited to the membrane where it adds a phosphate 
group to PI4,5P2 creating PI3,4,5P3.  PH domain containing proteins such as Akt and PDK1, are 
recruited to the membrane by PI3,4,5P3.  PDK1 phosphorylates Akt and activates it.  Active Akt 
has eight distinct downstream signal pathways.  Akt inhibits apoptosis by phosphorylating the 
proteins BAD and Caspase-9.  Akt also regulates several transcription factors either directly or 
indirectly.  Glucose storage is activated by Akt by phosphorylation and inactivation of GSK3.  
Active GSK3 phosphorylates and inhibits glycogen synthase (GS). Arrows denote upregulation 
wheareas squares represent down regulation or inhibition.  Modified from Song et al. (2005). 
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Caspases are a family of proteases that are quickly activated by proteolytic cleavage (Cho and 
Choi, 2002).  Caspase-9 is activated by cytochrome c release from the mitochondria (Donepudi 
and Grutter, 2002).  Caspase-9 is a member of a large multi-protein complex termed the 
apoptosome (Yuan et al., 1993).  When human caspase-9 is phosphorylated by Akt, its 
conformation interferes with its ability to trigger apoptosis via this cascade because it can no 
longer associate with the other proteins in the apoptosome (Donepudi and Grutter, 2002).   
Akt is capable of directly up-regulating or down-regulating several transcription factors 
involved in anti-apoptotic or pro-apoptotic gene expression, respectively.  Akt directly 
phosphorylates the foxO forkhead family of transcription factors (FKHR), decreasing expression 
of their pro-apoptotic target genes (Song et al., 2005).  Akt also phosphorylates cyclic AMP 
response element binding protein (CREB), which results in increased transcription of anti-
apoptotic genes (Song et al., 2005).  Akt indirectly regulates the transcription factors nuclear 
factor (NF)-κβ, p53 and p73 through phosphorylation of upstream proteins.  NF-κβ is involved 
in transcription of pro-survival genes whereas p53 and p73 are both involved in activating genes 
involved in apoptosis (Song et al., 2005).  Akt relieves inhibition of NF-κB and inhibits p53 and 
p73 (Song et al., 2005). 
Insulin signaling is mediated via the insulin RTK.  In the presence of insulin, Akt is involved 
in the metabolic regulation of cell survival through phosphorylation of glycogen synthase (GS) 
kinase 3 (GSK3) (Song et al., 2005).  GS is the rate-limiting enzyme of glycogen synthesis and 
when phosphorylated it is inactive (Welsh et al., 1996).  When GSK3 is phosphorylated by Akt, 
it is less active and increases glycogen synthesis by relieving inhibition of GS (Cross et al., 
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1995).   It was previously well established that inhibition of GSK3 is protective against apoptosis 
(Pap and Cooper, 1998), however emerging evidence is suggesting that GSK3 has anti-apoptotic 
functions (Meares and Jope, 2007).  GSK3 has several targets, besides its major substrate GS, 
including other signaling enzymes and transcription factors.  Recently, it was demonstrated that 
GSK3 contains a nuclear localization signal (NLS) and that phosphorylated GSK3 remains 
cytoplasmic in complexes with other proteins (Meares and Jope, 2007).  It has been reported that 
nuclear GSK3 promotes transcriptional activity of NF-κB, a pro-survival transcription factor 
(Hoeflich et al., 2000; Steinbrecher et al., 2005).  Thus, phosphorylated GSK3 is cytoplasmic, 
preventing apoptosis and dephosphorylated GSK3 is nuclear and promotes transcription of a pro-
survival transcription factor (Meares and Jope, 2007).  
  
1.4 PTEN Biological Function 
 
Various enzymes downstream of Akt contribute to PI3K/Akt signaling.  Phosphatase and 
tensin homolog deleted on chromosome ten (PTEN) inhibits all downstream PI3K pathway 
signaling at the source before amplification and thus it is the most important enzyme involved in 
regulating the PI3K/Akt signaling pathway (Sulis and Parsons, 2003).  PTEN, previously 
referred to as MMAC1 or TEP1, is a dual specificity lipid and protein tyrosine phosphatase 
(Sulis and Parsons, 2003).  The principle substrate of PTEN is PI3,4,5P3, the lipid second 
messenger generated by PI3K (Maehama and Dixon, 1998; Myers et al., 1998; Stambolic et al., 
1998).  PTEN prevents activation of Akt in the absence of growth factor, suggesting that PTEN 
is either inactivated upon growth factor stimulation or is activated by growth factor depletion 
(Cantley and Neel, 1999).  It is this lipid phosphatase activity that is the most biologically 
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relevant in qualifying PTEN as a tumor suppressor protein (Furnari et al., 1998).  Mutants that 
retain protein tyrosine phosphatase activity, but are unable to dephosphorylate PI3,4,5P3, have 
been found in tumors (Furnari et al., 1998; Lee et al., 1999; Myers et al., 1998).  Mutations such 
as G129E (glycine 129 changed to glutamate) and H93X (histidine 93 changed to any amino 
acid) have been observed frequently in cancers (Lee et al., 1999).   
PTEN is located on chromosome 10 at locus q23 and it is the deletion of this region in many 
cancers that results in loss of PTEN expression (Maehama and Dixon, 1999).    Heterozygous 
loss of PTEN leaves cells prone to tumor development (Trotman et al., 2003).  Single allele 
deletions are often observed in primary tumors, whereas the loss of the second PTEN allele is 
associated with advanced cancer and metastasis (Di Cristofano and Pandolfi, 2000; Trotman et 
al., 2003).  Many human metastatic cancers, including glioblastoma, melanoma, prostate and 
endometrial carcinoma, exhibit loss of PTEN expression (Miller et al., 2002; Ouchi et al., 2000).  
As well, a lack of PTEN activity can also result in non-malignant lesions in many of these tissues 
(Suzuki et al., 1998). 
PTEN gene deletion mice have been generated as a model for human cancers.  Knockout of 
PTEN in mice [PTEN(-/-)] is embryonic lethal (Simpson and Parsons, 2001).  Deletion of a 
single allele, or heterozygous PTEN [PTEN(+/-)] mice are viable but are prone to developing a 
variety of tumors, consistent with the established involvement of PTEN in tumor suppression (Di 
Cristofano et al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000; Suzuki et al., 1998).  
The location of these tumors include tissues of the breast, prostate, lung, endometrium, brain, 
thyroid, liver, lymphoid cancers and melanoma (Cantley and Neel, 1999; Goberdhan and Wilson, 
2003; Sansal and Sellers, 2004; Simpson and Parsons, 2001; Vivanco and Sawyers, 2002).  
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Heterozygous Pik3r1 [+/-] (encodes the α isoforms of p85, p55 & p50) that also contain half the 
normal level of PTEN,  i.e. PTEN(+/-), also display increased intestinal polyp incidence (~2-
fold)  and number (>3 per animal) compared to PTEN(+/-) mice (Luo et al., 2005).  This 
observation suggests that p85 may have a role in modulating tumor suppression by PTEN (Luo 
et al., 2005).   
 
1.5 The PTEN-p53 Tumor Suppression Connection 
 
PTEN is well recognized as a regulator of the PI3K/Akt pathway signaling and was initially 
suspected to remain in the cytoplasm in quiescent cells (Baker, 2007).  A growing body of 
evidence is implicating new PTEN functions in the nucleus (Baker, 2007).  The proto-oncogene 
murine double minute 2 (mdm2) is a downstream target of Akt signaling (Figure 1.9) (Woods 
and Vousden, 2001).  Mdm2 is a negative regulator of the well-studied tumor suppressor protein 
p53.  In contrast, PTEN lipid phosphatase activity has been shown to be a positive regulator of 
p53 through its attenuation of Akt signaling (Woods and Vousden, 2001).  However, PTEN also 
interacts with p53 in a phosphatase-independent manner and is involved in the acetylation of p53 
(Woods and Vousden, 2001). 
The p53 protein has been the most studied protein involved in apoptosis and is often deleted 
or non-functional in cancers.  Activation of p53 occurs in response to cell stress and it functions 
as a transcription factor that up-regulates the transcription of genes whose products are necessary 
for cell cycle arrest and/or apoptosis (Mayo et al., 2002).   Given the nature of p53’s primary 
function to arrest the cell cycle and induce apoptosis, it has a short half-life and is not very 
abundant in normal cells (Bates and Vousden, 1999; Levine, 1997).  The cellular stresses that  
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Figure 1.9: Regulation of p53 transcription and cellular concentration by mdm2.  Cellular 
stresses result in activation of p53.  p53 initiates transcription of apoptotic gene products.  A 
negative feedback loop is initiated by p53 via transcriptional activation of  mdm2.  Activated Akt 
promotes translocation of mdm2 into the nucleus through phosphorylation of mdm2.  mdm2 
binds nuclear p53, shuttles it to the cytoplasm and targets it for ubiquitin-mediated degradation. 
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activate p53 can be transient in nature, thus activation of p53 need not necessarily lead to cell 
death. Both regulation of p53 transcriptional activity as well as cellular protein stability is 
accomplished by the proto-oncogene mdm2 (Freedman et al., 1999).  The regulation of p53 
relies on an autoregulatory feedback loop in which p53 positively regulates mdm2 and in turn, 
mdm2 negatively regulates p53 (Wu et al., 1993).  Expression of p53 induces mdm2 expression, 
which binds the transcriptional activation domain of p53 and blocks the ability of p53 to recruit 
additional factors necessary for induction of gene expression (Chen et al., 1993; Momand et al., 
1992; Oliner et al., 1993).  Upon formation of the mdm2:p53 complex, p53 transcriptional 
activity is halted and the complex leaves the nucleus (Kubbutat et al., 1999; Roth et al., 1998; 
Tao and Levine, 1999).  In the cytoplasm, p53 is targeted for ubiquitin-mediated degradation by 
mdm2, which is an E3 ubiquitin ligase (Honda et al., 1997; Kubbutat et al., 1997).   
PI3K/Akt signaling promotes the translocation of mdm2 from the cytoplasm to the nucleus.  
The mdm2 protein is a substrate of the kinase Akt, which phosphorylates mdm2 at serine 
residues 166 and 186 (Mayo and Donner, 2001).  These serine residues are in proximity to a 
nuclear localization sequence and phosphorylation unmasks this region, allowing localization to 
the nucleus (Mayo and Donner, 2001).  PTEN is intrinsically linked to the regulation of p53 via 
negative regulation of PI3K/Akt signaling. 
PTEN also regulates p53 by a phosphorylation-independent mechanism via direct binding to 
the p53 protein in the nucleus (Freeman et al., 2003).  PTEN-knockout cells have dramatically 
reduced p53 levels; however, in the presence of the phosphatase inactive mutant PTEN-C124S, 
the level of p53 is increased (Freeman et al., 2003).  Furthermore, in addition to stabilizing and 
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increasing cellular levels of p53, PTEN also increases p53 promoter activity (Freeman et al., 
2003).     
The p53 protein is acetylated at several lysine residues located in the C-terminal regulatory 
domain (Gu and Roeder, 1997).  Acetylation is accomplished by the acetyltransferase p300/CBP 
in response to DNA damage and is implicated in p53 stability as well as the activation of p53 
sequence-specific DNA binding (Gu and Roeder, 1997; Li et al., 2002; Liu et al., 1999; Lohrum 
et al., 2001; Luo et al., 2004).  Acetylation of p53 is reversible and de-acetylation activity is 
provided by the PID-MTA2-HDAC1 complex (Luo et al., 2000) and Sir2α (Luo et al., 2001; 
Vaziri et al., 2001).   
PTEN stimulates p300-mediated acetylation through a phosphatase-independent mechanism 
by forming a PTEN-p300 complex in the nucleus (Li et al., 2006).  Overexpression of either 
PTEN or p300 results in higher p53 transcriptional activity (Freeman et al., 2003; Gu and 
Roeder, 1997).  However, overexpression of both PTEN and p300 synergistically increases p53 
transcriptional activation because acetylation of p53 greatly enhances PTEN binding (Li et al., 
2006). 
 
1.6 PTEN Structure and Function 
The physical properties of PTEN are a direct consequence of the domain structure of PTEN 
(Figure 1.10 a).  PTEN has an approximate mass of 55 kDa and is composed of 403 amino acids.  
PTEN has been described as having a domain structure consisting of a phosphatase (PASE) 
domain, required for phosphatase activity, a C2 domain involved in non-specific plasma 
membrane targeting, a regulatory domain containing PEST sequences and phosphorylation sites  
  29 
 
 
Figure 1.10:  Domain structure of PTEN and partial crystal structure illustrating clusters 
of basic amino acids.  (a) Domain structure of PTEN phosphatase.  PASE = phosphatase 
domain, C2 = C2 lipid binding domain, REG = regulatory domain, PDZB = PDZ binding motif.  
(b) Crystal structure of phosphatase and C2 domain of PTEN.  (L-tartrate is bound to the active 
site).  Obtained from: Lee et al. (1999). Produced by the National Center for Biotechnology 
Information, http://www.ncbi.nlm.nih.gov. Visualized, labeled and side chain color coding was 
performed using Cn3D v4.1. 
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and a PDZ binding domain (Figure 1.10 a).  Although PTEN has traditionally been described in 
this “domain” fashion, an emerging body of evidence is revealing that the PASE domain is 
essential for plasma membrane binding and the C2 domain is essential for phosphatase activity 
(Das et al., 2003).  Therefore, although PASE and C2 are referred to as domains, they should be 
considered as regions within a whole functional protein.  In addition, the partial crystal structure 
of the PTEN PASE and C2 domains shows extensive contacts between these two domains, 
suggesting their functions may be interdependent (Figure 1.10 b) (Lee et al., 1999).      
The PASE domain (aa 1-185) is in the N-terminal region and contains a phosphatase motif 
(HCXXGXXR; aa 123-130), which is required for catalytic activity (Simpson and Parsons, 
2001).  As with all phosphatases, changing the cysteine to a serine in the phosphatase motif 
results in an enzymatically dead mutant (C124S = Cys at position 124 mutated to Ser) (Barford, 
1996).  The full-length PTEN protein was tested for lipid binding affinity using a heterogeneous 
mixture of the anionic plasma membrane mimicking lipid vesicles 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS) 
and compared to the PASE domain (aa 1-185) (Das et al., 2003).  The affinity of the PASE 
domain (aa 1-185) for POPC/POPS vesicles was compared to full-length PTEN. Full-length 
PTEN had ~31-fold higher affinity for the vesicles than the PASE domain alone (Das et al., 
2003).  Two clusters of positive charge exist within the PASE domain consisting of 
R11/K13/R14/R15 and R161/K163/K164 (Figure 1.10 b) (Das et al., 2003; Lee et al., 1999).  
Both regions were mutated to alanine independently (PTEN-PASE-RKRR/AAAA and PTEN-
PASE-RKK/AAA, respectively) and tested for binding to lipid vesicles (Das et al., 2003). 
Mutations of both regions resulted in greatly reduced lipid binding, i.e. 76- and 22-fold, 
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respectively, but only the PTEN-PASE-RKK/AAA retained phosphatase activity (Das et al., 
2003).  Previous experiments altering regions of positive charge in the PASE domain had been 
executed by Lee and colleagues (1999) to examine the effects on intrinsic lipid phosphatase 
activity.  They created single mutations in the PASE domain at Thr167, Glu171, Lys128 and 
His93 (Lee et al., 1999).  In all instances, decreases in PTEN lipid phosphatase activity were 
observed in the range of 60-75% less lipid phosphatase activity (Lee et al., 1999). 
PTEN has a C2 domain that is located from residues 186 to 351.  Typically, C2 domains are 
Ca2+-dependent lipid binding domains found in proteins involved in cell signaling and membrane 
trafficking (Das et al., 2003).  The PTEN C2 domain is similar to some phosphatidylinositol 
specific phospholipases’ C2 domains (Georgescu et al., 1999).  However, the C2 domain of 
PTEN lacks all but one Ca2+-binding residues (Asp268) and has been implicated in Ca2+-
independent membrane localization as well as phospholipid binding (Georgescu et al., 1999; Lee 
et al., 1999; Simpson and Parsons, 2001).  Similar to the PASE domain, the isolated C2 domain 
also had significantly lower binding affinity (~30-fold decrease) for lipid vesicles POPC/POPS 
compared to full-length PTEN (Das et al., 2003).  Lee and colleagues also mutated two 
sequences in the C2 domain (263-K-M-L-K-K-D-K-269 to 263-A-A-G-A-A-D-A-269 and 327-
K-A-N-K-D-K-A-N-A-335 to 327-A-A-G-A-D-A-A-N-A-335) and in both cases observed 
decreased affinity for phosphatidylcholine (PC) lipid vesicles (Lee et al., 1999).  Cells 
expressing these mutants had a comparable phenotype to tumor-derived cells (Lee et al., 1999).   
Located near the C-terminal end from residues 350-375 and residues 379-396 are PEST 
sequences, which are degradation motifs frequently found in proteins that are degraded via the 
ubiquitin-mediated proteosomal pathway (Baker, 2007).  However, deletion of the PEST 
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sequences does not result in more PTEN protein, but, in fact, leads to decreased protein 
expression, suggesting that the PEST sequences must be required for proper protein folding 
(Simpson and Parsons, 2001; Vazquez et al., 2000).  Recently, the ubiquitin ligase Nedd4-1 has 
been implicated in PTEN ubiquitin-mediated degradation and may even be functioning as an 
oncogene in some cancers due to its ability to decrease cellular PTEN levels (Wang et al., 2007).  
The C-terminal region of PTEN has a regulatory domain that contains phosphorylation sites 
for casein kinase 2 that are phosphorylated in a hierarchical fashion with the primary sites being 
S370 and S385 followed by residues S380, T382, T383 and possibly T366 (Torres and Pulido, 
2001).  Phosphorylation of PTEN stabilizes it and localizes it to the cytoplasm (Das et al., 2003; 
Torres and Pulido, 2001).  It has been proposed that upon phosphorylation, the regulatory 
domain blocks the ability of PTEN to localize to the plasma membrane via an electrostatic 
interaction with the phosphatase domain (Torres and Pulido, 2001).  Mutations resulting in 
constitutive dephosphorylation of S380, T382 and T383 or deletion of these residues results in a 
constitutively plasma membrane-localized PTEN mutant (Das et al., 2003).  The 
phosphorylation sites are important for the stability and activity of PTEN as mutations in the C-
terminal region of PTEN reverse the tumor suppressing phenotype (Georgescu et al., 1999).  
Phosphorylation of S370 and S385 by casein kinase 2 inhibits phosphatase activity (Miller et al., 
2002) and interestingly also inhibits cleavage of PTEN by the protease caspase-3 (Torres et al., 
2003).  Therefore a phosphatase is required to dephosphorylate and activate PTEN so it can 
interact with the plasma membrane and then be quickly degraded.  Currently no phosphatase that 
has PTEN as a substrate has been identified.  Cells expressing a PTEN mutant lacking the C-
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terminal regulatory domain have increased PTEN activity (Vazquez et al., 2001) and constitutive 
plasma membrane localization of the protein (Das et al., 2003).     
PTEN has also been shown to translocate into the nucleus where it is acetylated (Okumura et 
al., 2006).  Since PTEN interacts with p53 as well as p300 in the nucleus, there are several 
suggestions as to how the PTEN protein enters the nucleus including passive diffusion, a C-
terminal nuclear import signal (Lian and Di Cristofano, 2005), an N-terminal nuclear import 
signal (Gil et al., 2006) or it may be carried in by another protein.   
PCAF (p300/CBP-associated factor) interacts with PTEN at amino acids 186-202 (Okumura 
et al., 2006), a region previously characterized as the hinge region between the N-terminal 
phosphatase domain and the C-terminal C2 domain (Lee et al., 1999).  Wild type (wt) PTEN and 
PCAF co-localize to the nucleus in untreated cells, but PTEN ∆186-202 is excluded from the 
nucleus, suggesting that PCAF chaperones PTEN into the nucleus (Okumura et al., 2006).  A 
more recent study demonstrated that PTEN is mono-ubiquitinated by Nedd4-1 at lysine 289 and 
also translocates to the nucleus (Trotman et al., 2007).  PTEN is acetylated by PCAF at lysine 
residues 125 and 128, which interferes with PTEN phosphatase signaling and diminishes the 
ability of PTEN to arrest cell cycle entry (Okumura et al., 2006). 
A number of elegant experiments have been executed by the Cho laboratory at the University 
of Chicago involving PTEN mutants and truncations fused to green fluorescent protein (GFP) 
(Das et al., 2003).  All of the PTEN variants that included the PASE domain also incorporated a 
C124A (cysteine to alanine) mutation in the phosphatase motif in order to abolish PTEN 
phosphatase activity because active PTEN was not visible for imaging (Das et al., 2003).  
Presumably, the inability to visualize enzymatically active PTEN was that some aspect of PTEN 
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signaling results in expedient degradation after translocation to the plasma membrane (Das et al., 
2003).  All of the images were generated in the context of normal unstimulated HEK293 cells, 
which had the growth medium replaced with 1 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.4 (Das et al., 2003).  GFP-PTEN-C124A was 
observed in the cytoplasm; however, removal of the regulatory domain (aa 353-403) resulted in 
constitutive plasma membrane localization of the protein.  Interestingly, deletion of the 
regulatory domain together with mutation of a cluster of basic amino acids in the PASE domain 
(R161/K163/R164) abolished plasma membrane localization.  Similar to deletion of the 
regulatory domain, substitution of amino acids S380, T382 and T383 to alanine (STT/AAA; can 
not be phosphorylated) also resulted in constitutive plasma membrane localization (Das et al., 
2003).  Mutation of the same amino acids to glutamate (STT/EEE; phosphorylation mimic) 
resulted in cytoplasmic localization (Das et al., 2003).  The isolated C2 domain was also 
distributed throughout the cytoplasm. 
In tissue extracts, PTEN exists within a large multi-protein complex termed the “PTEN 
associated complex” (PAC) (Wu et al., 2000a).  The PAC contains the proteins MAGI-2, PTEN 
and p85 (Figure 1.11) (Wu et al., 2000a).   PTEN has a PSD-95/Dlg/ZO-1 (PDZ) binding motif 
that facilitates binding to one of the PDZ domains of the scaffolding protein membrane 
associated guanylate kinase inverted-2 (MAGI-2) and MAGI-3, members of the MAGUK 
protein family (Wu et al., 2000a).  MAGI-2 contains six PDZ domains, two WW domains (bind 
proline-rich sequences) and a guanylate kinase-like (GuK) domain that is catalytically inactive 
(Wu et al., 2000a).  MAGI proteins are cytoplasmic in quiescent cells, but translocate to the 
plasma membrane upon receptor activation (Xu et al., 2001), where they bind to various 
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Figure 1.11: Model of the relationship between free p85, PI3K hetero dimer and PTEN in a 
cell. Casein kinase 2 phosphorylates the regulatory domain of PTEN, which results in the 
cytosolic closed conformation.  The reverse reaction is catalyzed by an unidentified phosphatase, 
which causes PTEN to adopt an open conformation and non-specifically localize to the plasma 
membrane. At the plasma membrane, the scaffolding protein MAGI forms a complex with p85 
and PTEN that may localize PTEN near activated receptors where it can dephosphorylate its 
substrate PI3,4,5P3.  
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receptors, including G-protein coupled receptors, ion channel receptors and some RTKs via their 
PDZ domains (Kaech et al., 1998; Shiratsuchi et al., 1998; Wu et al., 2000b). 
Recently, a graduate student in our laboratory, Ryaz Chagpar, has shown that p85 binds to 
PTEN and increases PTEN lipid phosphatase activity (Chagpar, 2004).  Since the cellular 
concentration of p85 is higher than that of p110, with approximately 70% of the p85 in a cell 
associated with p110 (Ueki et al., 2002), we hypothesized that the free p85 may be involved in 
PTEN regulation.  We have incorporated this information into a model for PTEN regulation 
(Figure 1.11).  Casein kinase 2 phosphorylates the regulatory domain of PTEN resulting in the 
cytoplasmic closed conformation.  The reverse reaction is catalyzed by an unidentified 
phosphatase.  PTEN adopts an open conformation and non-specifically localizes to the plasma 
membrane through electrostatic interactions between the basic surfaces on the PASE and C2 
domains and the anionic lipids of the plasma membrane.  At the plasma membrane, the 
scaffolding protein, MAGI-2 forms a complex with p85 and PTEN that may allow p85 to 
positively regulate PTEN activity.  While MAGI-2 proteins have not yet been shown to bind to 
RTKs in mammalian cells, we hypothesize that they do via one of their six PDZ domains, and 
that this would serve to localize PTEN at the receptor sites where PI3,4,5P3 lipids have recently 
been generated.  In order for RTK signaling to be efficient, highly regulated and expedient 
attenuation is required.  Localization and activation of PTEN within the PAC would allow for 
only a transient activation of the PI3K/Akt pathway resulting in rapid attenuation of RTK 
signaling.     
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2.0 RATIONALE AND OBJECTIVES 
 
One well-established role for the p85 regulatory subunit of PI3K is to stabilize, regulate and 
target the p110 PI3K catalytic subunit to the plasma membrane upon growth factor stimulation.  
The molar ratio for p85:p110 in a cell is not 1:1 as approximately only 70% of cellular p85 is 
associated with p110 (Ueki et al., 2002).  Some of the “free” p85 may be involved in attenuating 
growth factor signaling by acting as a dominant negative because p85 that is not in a complex 
with p110 is still capable of binding the phosphotyrosines of an activated RTK.  Thus, p85 can 
occupy a binding site that the catalytically active p85:p110 could otherwise have occupied.  Our 
laboratory has shown that p85 has the ability to bind to and upregulate the lipid phosphatase 
activity of PTEN (Chagpar, 2004) and that this requires the N-terminal SH3 + BH domains of 
p85 (D. Anderson, unpublished observations). 
Characterization of functional domains within PTEN demonstrates that the binding to 
membrane lipids and lipid substrate requires both the PASE and C2 domains (Das et al., 2003).  
The regulatory domain does not play an important role in the physical lipid binding properties of 
PTEN, but is responsible for transition between the proposed open and closed conformations of 
PTEN.  Removal of the regulatory domain or even alanine substitution of the S380/T382/T383 
phosphorylation sites results in a constitutively plasma membrane-localized protein (Das et al., 
2003).   
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A cluster of positively charged residues in the PASE domain of PTEN have been identified to 
be important in non-specific membrane targeting.  When this cluster of basic residues is mutated 
to alanine and the regulatory domain is removed, the ability to localize to the plasma membrane 
is abolished (Das et al., 2003).  We examined the partial crystal structure of PTEN and observed 
that two more clusters of positively charged residues were on the same surface of the protein but 
were located in the C2 domain of PTEN (Lee et al., 1999).  Further analysis of the PTEN crystal 
structure revealed Tyr336 located on the same basic surface of the C2 domain (Lee et al., 1999).  
This residue may have implications in regulation of disengagement of PTEN from the plasma 
membrane.  
Hypothesis: The p85 protein increases PTEN lipid phosphatase activity.  Regulation of PTEN 
is dependent on whether the protein is in an open or closed conformation.  The casein kinase 2 
phosphorylation sites, i.e. S380/T382/T383, regulate which conformation PTEN adopts 
(phosphorylation = closed; no phosphorylation = open).  PTEN has positively charged surfaces 
important for plasma membrane targeting.  In the closed conformation, the phosphate groups in 
the regulatory domain mask clusters of positive charge located in the PASE and C2 domains and 
PTEN remains cytoplasmic.  Dephosphorylation of these regulatory phosphorylation sites allows 
PTEN to adopt an open conformation and localize non-specifically to the plasma membrane 
upon growth factor stimulation.  At the plasma membrane PTEN is targeted to the active receptor 
where it is in proximity to its substrate and PTEN activity is enhanced by the p85 protein. 
Objectives: The focus of this thesis was to characterize in more detail the activation of PTEN 
lipid phosphatase activity by p85 in vitro and to carry out a structure/function analysis of PTEN.  
The specific objectives are as follows:  
1.  Modify an existing PTEN enzymatic assay to measure activation by p85. 
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2.  Structure/function analysis of PTEN – Site-directed mutagenesis was employed to create 
phosphorylated and unphosphorylated mimics of regulatory domain phosphorylation sites 
(S380/T382/T383) and a potential phosphorylation site (Y336) that may have a role in plasma 
membrane localization.  The technique was also used to substitute clusters of positively charged 
residues, thought to be important for an electrostatic interaction with the anionic plasma 
membrane, with alanine residues. 
2.1 Test lipid binding properties of wild type PTEN and the PTEN mutants.  
2.2 Assess the subcellular localization of wild type PTEN and PTEN mutants under 
unstimulated and EGF stimulated conditions. 
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3.0 MATERIALS & METHODS 
 
3.1 Materials 
 
3.1.1 Mammalian cells 
 
Human embryonic kidney 293 (HEK293) cells were obtained from American Type Cell 
Culture. 
 
3.1.2 Bacterial strains & growth media 
 
Plasmid DNA was amplified using Escherichia coli (E. coli) strain TOP10 [F-, mcrA, D(mrr-
hsdRMS-mcrBC), f80lacZDM15 DlacX74, deoR, recA1, araD139 D(ara-leu)7697, galK, 
rpsL(StrR), endA1, nupG] (Invitrogen).  Overexpression of recombinant GST-p85 proteins was 
performed using an E. coli strain deficient in protease activity, BL21 (DE3) [E. coli B, F-, dcm, 
ompT, hsdS(rB-mB-), gal] (Pharmacia). Overexpression of His6-PTEN, His6-PTEN-C124S and 
the various His6-PTEN-C124S mutants was accomplished using M15[pREP4] derived from E. 
coli strain K12 NalS, StrS, RifS, Thi-, Lac-, Ara+, Gal+, Mtl-, F-, RecA+, Uvr+, Lon+ (Qiagen).  All 
bacterial strains were grown in Millar’s Luria-Bertani broth (LB, Sigma) containing 10.0 g 
tryptone, 5.0 g yeast extract and 10.0 g NaCl per litre.  The media was supplemented with either 
100 µg/mL ampicillin (LBA) or 50 µg/mL of kanamycin (LBK) depending on whether the 
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transforming plasmid contained ampicillin resistance (AmpR) or kanamycin resistance (KanR), 
respectively.  Bacterial cells were grown at 37 °C in a shaking incubator unless otherwise noted. 
 
3.1.3 Immunoblot detection antibodies 
 
For brevity and conciseness, all antibodies are listed in Table 3.1. 
 
3.1.4 PTEN enzyme fluorescent substrate 
 
The fluorescently-tagged PI3,4,5P3 lipid substrate was NBD6-PtdIns(3,4,5)P3 and was 
obtained from Echelon Biosciences; catalogue number C-39N6. 
 
3.1.5 Plasmids and vectors 
 
The full-length PTEN cDNA encoding amino acids 1-403 was cloned by R. Chagpar 
(University of Saskatchewan) from HeLa cells using RT-PCR and subcloned into the pGEX-6P1 
vector (Amersham Pharmacia).  The phosphatase-inactivating mutation C124S was introduced 
using site-directed mutagenesis (Chagpar, 2004).  The PTENwt aa 1-403 and PTEN-C124S aa 1-
403 cDNA genes were subcloned from pGEX-6P1 to the  pQE9 vector (Qiagen) by D. Anderson 
(Saskatchewan Cancer Agency). The pQE9-PTENwt and pQE9-PTEN-C124S were used to 
express His6-PTEN fusion proteins in bacteria.  The mutants PTEN-C124S-STT/AAA, PTEN-
C124S-STT/EEE, PTEN-C124S-C2-K3A, PTEN-C124S-C2-K5A, PTEN-C124S-PASE-
RKK/AAA, PTEN-C124S-Y336A and PTEN-C124S-Y336E were generated in the pEGFP 
(Invitrogen) vector and subcloned into to pQE9 by S. Knafelc (University of Saskatchewan).  
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Table 3.1: Primary and secondary antibodies used to probe protein and lipid blots 
Antibody + Concentration Company, Catalog # Figures 
PTEN A2B1 mouse monoclonal 
1µg/mL 
Sana Cruz Biotechnology, sc7974 4.3, 4.4 
PTEN A2B1 mouse momoclonal 
horseradish peroxidase (HRP) 
1µg/mL 
Santa Cruz, Biotechnology, sc7974 4.1, 4.4 
IRDye 680 conjugatede goat 
(polyclonal) anti-mouse IgG 
1:2000 
LI-COR Biosciences, 926-32220 4.3, 4.4 
p85 NSH@ mouse monoclonal 
1:500 
Upstate Biotechnology 05-217 4.2 
Goat anti-mouse IgG HRP 1:500 Santa Cruz Biotechnology, sc2055 4.2 
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The bovine p85α wild type protein aa 1-724 was obtained in the pGEX-2T vector from M. 
Waterfield (London, UK).  The mammalian expression vector pEGFP was obtained from 
Invitrogen.  Subcloning of the PTEN wt aa 1-403 and PTEN-C124S aa 1-403 cDNAs was 
performed by R. Chagpar. 
 
3.1.6 Lipid Blots  
 
Lipid blots (PIP strips) were obtained from Echelon Biosciences and are nitrocellulose 
membranes spotted with 100 pmol of lipid/spot (catalogue #P6001).  The lipids spotted were: 
lysophosphatidic acid (LPA), lysophosphocholine (LPC), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylinositol 
(PI), PI 3-phosphate (PI3P), PI4P, PI5P, PI3,4P2, PI3,5P2, PI4,5P2, PI3,4,5P3, and sphingosine 1-
phosphate (S1P). 
 
3.1.7 Other reagents and supplies 
 
Chemicals used were purchased from VWR or Sigma and were of analytical grade or higher 
quality unless otherwise noted.  
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3.2 Methods 
 
3.2.1 DNA methods 
 
3.2.1.1 Plasmid preparation 
 
Generally, all plasmids with the p85α or PTEN cDNA inserts were transformed into 
competent E. coli, selected for on LB agar containing the appropriate antibiotic (ampicillin for 
pGEX and pQE9, kanamycin for pEGFP), grown overnight in LB containing the appropriate 
antibiotic and stored at -80 °C in 20 % glycerol (Elbing, 2002).  Plasmid DNA of high yield and 
purity was obtained from overnight cultures using a QIAprep Spin Miniprep Kit (catalogue 
#27104) or a HiSpeed Plasmid Maxi Kit (catalogue #12662) obtained from Qiagen.  The DNA 
purification kits were used in accordance with the manufacturer’s instructions with the alteration 
that DNA was eluted with water instead of elution buffer.  This change was made because dH2O 
did not contain salts that may have to be considered later when using the DNA for transfections.  
Mini-preps were eluted by applying 20 µl dH2O to the column, incubating at 55 °C for 5 minutes 
followed by centrifugation at 18,000 x g.  Since only 20 µl of dH2O was used instead of the 
recommended 50 µl, the eluted DNA and water was reapplied to the column a second time, 
incubated at 55 °C for 5 minutes and centrifuged at 18,000 x g.  Maxi-preps were eluted using 
500 µL of dH20 instead of elution buffer.  DNA quantification was determined by performing a 
1:25 dilution in dH2O and reading the absorbance at a wavelength of 260 nm.  Relative purity 
was performed by calculating the ratio of the absorbance at 260 nm divided by the absorbance at 
280 nm using an Amersham Pharmacia Ultraspec 3100 spectrophotometer programmed for DNA 
quantification mode. 
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3.2.1.2 Site-directed mutagenesis 
 
Seven PTEN C124S mutants were created using site-directed mutagenesis.  The starting 
template for all of the mutants was pEGFP-PTEN-C124S aa 1-403 (Chagpar, 2004).  All of the 
primers used were custom-ordered from Invitrogen Life Technologies in sense/anti-sense pairs.  
For brevity only the sense primer names and sequences will be noted as in all instances the 
reverse complement primer was identically named with the exception of the 3' designation 
preceding the name instead of 5' (Figure 3.1). 
Mutagenesis reactions were performed in 50 µl of Pfu buffer –MgSO4 (Fermentas) with 2.5 U 
of Pfu DNA polymerase (Fermentas), 1 ng template DNA, 2.5 ng each of sense and anti-sense 
primers and 50 µM dNTPs.  The thermocycler program used was as follows: 95 °C for 1 minute 
followed by 14 cycles of 95 °C for 30 seconds, 54 °C for one minute and 68 °C for 17 minutes.  
A single final extension step of 72 °C for 7 minutes was added to the end of the program.  Tubes 
were centrifuged 18,000 x g for 30 s and 10 U of Dpn I (Fermentas) was added and mixed by 
pipetting the mixture several times.  The mixture was incubated at 37 °C for 1 h to allow the Dpn 
I to digest the methylated wild type template DNA.  Forty µl was used to transform competent 
TOP10 bacteria (Elbing, 2002), which were plated onto warm LB agar plates containing 15 
µg/ml kanamycin.  The plates were incubated overnight at 37 °C and the smallest colonies were 
inoculated into 5 mL of LBK and grown overnight at 37 °C in a shaking incubator on a setting of 
250-300 rpm.  Plasmid DNA was prepared as stated previously.  The plasmid DNA was 
submitted to the DNA Technologies Unit at the Plant Biotechnology Institute (Saskatchewan) for 
sequencing to verify that the desired mutation(s) were introduced.  The primers included with  
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the plasmid DNA for the sequencing reaction were 5' seqEFP and 5' PTENC124S.    
The two mutants GFP-PTEN-C124S-Y336E and GFP-PTEN-C124S-Y336A were generated 
using a single set of degenerate primers that would alter the codon for tyrosine at position 336 
from UAC to either GAA or GCA, resulting in an amino acid change to glutamic acid or alanine, 
respectively.  The sense primer used for these mutants was 5'PTEN Y336E/A and the sequence 
was 5' GCC AAC CGA G(A/C)A TTT TCT CCA AAT. 
 The GFP-PTEN-C124S-STT/AAA mutant was generated using a single set of primers to 
change all three codons.  The primer used was named 5'PTENCKII-U and its sequence was 5' 
CAT TAT AGA TAT GCT GAC GCC GCT GAC TCT GAT CC.  
The remaining four mutants that had multiple amino acid changes were generated using a 
sequential approach using one set of primers per triplet codon change (Figure 3.1).  These four 
mutants were GFP-PTEN-C124S-STT/EEE, GFP-PTEN-C124S-C2K3A, GFP-PTEN-C124S-
C2K5A and GFP-PTEN-C124S-PASE-RKK/AAA.  Upon successful mutagenesis, the new 
mutant was labeled according to the primer name for the mutation made e.g. GFP-PTEN-C124S-
T382E.  After verification by DNA sequencing GFP-PTEN-C124S-T382E became the template 
for the next round of mutagenesis.  The primers were designed to overlap such that the set of 
primers to mutate the next amino acid incorporated the previous mutation and the resultant 
mutant was named GFP-PTEN-C124S-T382/T383E and so on for the remaining mutation as 
well as the three other GFP-PTEN-C124S mutants. 
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3.2.1.3 Subcloning   
  
Subcloning the PTEN mutants from the EGFP vector to the pQE9 vector was accomplished 
by Stacey Knafelc (Summer student, 2006), by digesting 2 µg each of pEGFP-PTEN-mutant 
vector and pQE9 vector in One-Phor-All Buffer PLUS (GE Healthcare, NJ USA)  for 1h at 37 
°C using 50 U of Bgl II and 60 U Sal I purchased from New England Biolabs (MA, USA).    
Fragments were electrophoresed using a 1% low melt agarose gel (Sigma, catalogue # 9012-36-
6).  The appropriate pQE9 vector and PTEN insert DNA fragments were excised from the gel 
and purified using a Qiagen gel extraction kit in accordance with the manufacturer’s instructions 
except that the final elution was performed with dH2O.  Ligation into the pQE9 vector was 
accomplished using Quick ligase in accordance with the manufacturer’s instructions (New 
England Biolabs, MA, USA).  The entire ligation mixture was used to transform competent 
TOP10 cells as previously stated (Elbing, 2002). 
 
3.2.2 Protein analysis 
 
3.2.2.1 Induction and affinity purification of His6-fusion proteins 
 
His6-PTEN proteins were expressed and purified by Stacey Knafelc (Summer student 2006).  
The PTEN wt and mutants C124S, C124S-STT/AAA, C124S-STT/EEE, C124S-C2-K3A, 
C124S-C2-K5A, C124S-PASE-RKK/AAA, C124S-Y336A and C124S-Y336E were expressed 
individually using the pQE9 vector transformed into M15pREP4 cells. pQE9-PTEN-C124S was 
previously generated by D Anderson (Saskatchewan Cancer Agency, Canada).  The M15pREP4 
cells containing the respective plasmids were each inoculated into 100 mL of LB growth medium 
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containing ampicillin and grown overnight at 37 °C in a shaking incubator.  Sixteen – twenty 
four hours after inoculation, the culture was added to 1L of similar media and grown to an 
optical density of 0.6 at A600.  The culture was cooled to room temperature and protein 
production was induced using isopropyl β-D-thiogalactopyranoside (IPTG; Sigma catalogue # I-
5502) at a final concentration of 0.3 mM.  Induction was carried out overnight at room 
temperature.  The bacterial cultures were subjected to centrifugation at 5,000 x g for 10 minutes.  
Lysis of the pellets was performed in 8 ml of lysis buffer per 1.4 g of cells.  The lysis buffer was 
50 mM NaH2P04 pH 8.0 containing 300 mM NaCl, 10 mM imidazole, 1 mg/ml lysozyme, 1 mM 
4-(2-aminoethyl)-benzenesulfonylfluoride (AEBSF) and 5 mM β-mercaptoethanol.  The 
suspensions were vortexed, incubated for 1 h at 4 °C, and 25 ml aliquots were sonicated 3 times 
for 10 seconds at 4 °C at a setting of 2.5 with a Branson Sonifier 450 fitted with a micro tip.  
Centrifugation at 24,000 x g removed cell debris and the supernatant was subjected to affinity 
chromatography.  It was discovered that using the Qiagen Ni-NTA agarose purification kit, but 
substituting Talon metal affinity resin (Clontech) for the Ni-NTA resin, resulted in the highest 
yield of relatively pure protein.  Thus the Qiagen protocol was employed using the Clontech 
resin.  The lysate and resin were divided into two 50 mL tubes (Falcon) and nutated at 4 °C for 1 
h.  The tubes were centrifuged at 4 °C at 834 x g for 5 minutes in a Sorvall RT6000D benchtop 
centrifuge equipped with a H1000B rotor.  The supernatant was removed and the resin was 
washed with Qiagen wash buffer (8 M urea, 100 mM NaH2PO4, 10 mM Tris Cl, pH 6.3, 1 mM 
tris(2-carbosyethyl)phosphine (TCEP) added just before use), centrifuged at 834 x g and the 
supernatant removed.  A Bradford protein determination (BioRad) was performed on the wash 
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buffer supernatant and multiple washes were performed until no protein  was detected in the 
wash buffer (Qiagen) supernatant.  The resin was transferred to a TALON 2 mL disposable 
column (Clontech) and 10 mL of Qiagen elution buffer (8 M urea,100 mM NaH2PO4, 10 mM 
Tris Cl, 10 mM imidazole, pH 6.3, 1 mM TCEP added just before use) was applied to the 
column.  One mL aliquots were collected from the column and the protein concentration of each 
aliquot was verified using a Bradford assay.  The content and purity of each aliquot was assessed 
by using SDS-PAGE (10%) followed by Coomassie Blue stain (Sasse, 2003).  Typically, elution 
aliquots 2-8 were pooled and applied to an Amicon Ultra Concentrator dual membrane with a 
10,000 Da molecular weight cut off (Millipore, MA, USA).  The concentrator was used in 
accordance with the manufacturer’s instructions to buffer-exchange the His6-PTEN proteins into 
PTEN storage buffer (50 mM Tris pH 8.0, 1 mM EDTA, 150 mM NaCl, 2 mM DTT added 
fresh).     
Protein concentration was determined using the Bradford assay.  Analysis of the purity of the 
recombinant protein was performed using SDS-PAGE followed by staining with Coomassie 
Blue stain (Elbing, 2002).  The proteins were also resolved by SDS-PAGE (10%) and transferred 
to nitrocellulose using an Owl semi-dry transfer apparatus.  The nitrocellulose membrane was 
soaked in dH2O for 15 minutes prior to transferring.  The resolved polyacrylamide gel and eight 
pieces of 3MM paper (Whatman) cut to the same size as the gel were incubated in transfer buffer 
(50 mM Tris, 37 mM glycine, 1.3 mM SDS, pH 9.2 ) for 15 minutes.  The transfer apparatus 
required dH2O on the graphite electrode and was assembled according to the manufacturer’s 
instructions.  The transfer was performed at constant milliamperage of 400 for 15 minutes.  The 
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nitrocellulose membrane was blocked in TBST containing milk (5% w/v) for 1 h.  The blot was 
probed overnight with a horseradish peroxidase-conjugated PTEN monoclonal antibody at a 
concentration of 1 µg/mL in TBST containing milk (5% w/v) and visualized with 
chemiluminescence according to the manufacturer’s instructions (Perkin Elmer).  Film was 
obtained from Kodak (X-OMAT AR, 8 x 10 inches, catalogue # 165 1454).  
 
3.2.2.2 Induction and affinity purification of GST-fusion proteins 
 
The pGEX-2T-p85 plasmid was transferred into BL21 (DE3) cells that were treated in the 
same fashion as the pQE9-PTEN plasmids with the alteration that the induction was performed 
with 0.1 mM IPTG at room temperature for 5 h.  The cells were collected and lysed in phosphate 
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3) 
containing AEBSF (1 mM), aprotinin (10 µg/ml)  and leupeptin (10 µg/ml)  as previously stated 
with the alteration that the affinity chromatography was performed using glutathione-Sepharose 
resin, and the p85 protein was cleaved from the GST portion and beads with Thrombin (Sigma) 
according to the method previously published (Current Protocols in Molecular Biology, Section 
16.4.8).  The immobilized GST-p85 on beads was cleaved with Thrombin (5 U/mg protein) in 
PBS overnight at room temperature.  Protein concentrating, quantification and verification of 
purity were performed using the same method as used for the His6-PTEN proteins.  For 
concentrating, a concentrator with a 30,000 Da molecular weight cut-off was used.  The 
Bradford assay was used to determine protein concentration and purity was assessed using SDS-
PAGE and Coomassie Blue staining. 
 
  52 
3.2.2.3 Fluorescent PTEN enzyme activity assay 
 
The fluorescent PTEN enzyme activity assay was adapted from Taylor and Dixon (2001).  
The reaction was performed in a total volume of 20 µl of 50 mM Tris HCl pH 8.0, 1 mM EDTA, 
150 mM NaCl with 2 mM DTT (added fresh) with 1.5 µg fluorescent lipid substrate [NBD6-
Ptdns(3,4,5)P3] and different concentrations of proteins (His6PTEN +/- p85).  The reactions were 
quenched with 100 µl of acetone and dried in a “speed vac” with warming.  Dried lipids were 
resuspended in 9 µl of 5:5:2 methanol:2-propanol:glacial acetic acid and spotted onto a 20 x 20 
cm  LK6  silica  gel  60  Ǻ   thin  layer  chromatography  (TLC)  plate  (catalog  #4865-820, 
Whatman Inc.).  The  TLC  plate  was  developed  for  20  minutes  in  a  sealed  chromatography  
chamber equilibrated with the following developing solvent: 70:50:20:20:20 
chloroform:methanol:acetone:glacial acetic acid:dH2O.  The TLC plate was visualized using a 
BioRad Gel Doc UV transilluminator and fluorescent spot quantification was performed using 
BioRad Quantity One software.  Local background subtraction was used.  For the PTEN 
titration, the average across three independent replicates was plotted using Graphpad Prism 
software v4.0.  It was determined that 0.56 µM His6-PTEN would convert approximately 40% of 
1.5 µg of fluorescent PI3,4,5P3 substrate, NBD6-Ptdns(3,4,5)P3, to PI4,5P2 product in a reaction 
time of 20 minutes at 37 °C.  To measure the effect of p85 on PTEN activity, p85 was added at 
concentrations of 0.14, 0.28, 0.56 and 1.12 µM, keeping a constant concentration of His6-PTEN 
protein (0.56 µM).  Duplicate p85 addition experiments were plotted separately using GraphPad 
Prism 4.0. 
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3.2.2.4 Lipid blot binding 
 
The nitrocellulose membranes spotted with various lipids (see section 3.1.6) obtained from 
Echelon Biosciences were blocked for 1 h at room temperature in blocking buffer (fatty acid-free 
BSA 3% w/v [Sigma; catalogue #A0281] in 10 mM Tris/HCl pH 8.0, 150 mM NaCl and 0.1% 
v/v Tween-20).  The blots were incubated overnight at 4 °C with 2 µg His6-PTEN in 2 ml of 
blocking buffer.  The membranes were washed six times with blocking buffer for 5 minutes per 
wash on a Rocking Platform (VWR).  The blots were probed with 1 µg/ml PTEN A2B1 antibody 
in blocking buffer for 1 h at room temperature.  The blots were washed again as before and 
probed with a 1:2000 dilution of IRDye 680 goat anti-mouse antibody in blocking buffer for 1 h 
at room temperature.  The blots were washed and scanned using the Odyssey imaging system 
(LI-COR Biosciences; Nebraska, USA) at 700 nm.  The brightness and contrast were set to level 
50 and a sensitivity setting of 5 in the linear mode.  Quantification was performed using the 
Odyssey v2.1 software.  The blots were normalized to PI4,5P2 levels in the PTEN-C124S 
samples across the replicates because it was the spot with the least variation.  For each PTEN 
protein, at least three independent experiments were carried out and a new lipid blot 
nitrocellulose membrane was used.  The lipid blot data was analyzed using the Odyssey 2.1 
software for quantification with local background subtraction.  Statistical differences were 
calculated using a matched pairs t-test with a confidence interval of at least 95%.  The values 
calculated are listed in Appendix 1. 
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3.2.3 Microscopy 
 
3.2.3.1 Cell culture technique 
 
HEK293 cells were maintained in Alpha Modified Eagle’s Medium (αMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS, VWR), 100 U/ml penicillin G and 100 µg/ml 
streptomycin (1% P/S).  The cells were grown at a temperature of 37 °C with the level of CO2 
enriched to 5%.  
 
3.2.3.2 Transfection of HEK293 cells with pEGFP-PTEN-C124S plasmids 
 
HEK293 cells, at a concentration of 200,000 cells/mL, were seeded onto #1.5 coverslips 
(VWR) in a tissue culture plate, 6 well (Falcon), in culture media and the cells were grown 
overnight.  Briefly, 1 µg of DNA was transfected into cells using Lipofectamine Plus 
(Invitrogen) in accordance with the manufacturer’s instructions optimized for 6 well tissue 
culture plates.  The DNA, 100 µL of Opti-MEM (Invitrogen; catalogue # 11058), and 6 µl of 
PLUS reagent (Invitrogen) were incubated at room temperature for 15 minutes.  Four µl of 
Lipofectamine was added to 100 µl of Opti-MEM and this was added to the DNA mixture.  After 
incubating for 15 minutes at room temperature, 800 µl of warm serum-free αMEM was added.  
The cells were washed with 500 µL of warm serum free αMEM and the transfection media was 
added.  After a 5 h incubation at 37 °C and 5% CO2, 1 mL of αMEM containing 20% FBS was 
added to the 1 mL of serum-free transfection media in the well resulting in a final concentration 
of 10% FBS.  Twenty four h after adding the transfection media, 1 mL of the media was 
removed, and epidermal growth factor (Sigma; catalogue # E-9644) was added to a concentration 
of 80 nM.  The EGF containing media was used to stimulate the cells for 5 minutes.  Following 
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stimulation, cells were immediately washed once with 0.5 mL of ice-cold PBS and fixed with 
4% paraformaldehyde (Electron Microscopy Sciences, PA, USA) for 30 minutes at room 
temperature.  Coverslips were mounted directly on slides using Prolong Gold mounting media 
(Invitrogen).   
 
3.2.3.3 Confocal image acquisition 
 
Imaging of the cells was performed by using an Olympus FluoView 300 point-scanning, 
point-detection, confocal laser-scanning microscope (Neuropsychiatry Research Unit, University 
of Saskatchewan). The 10x objective lens was used in fluorescence mode to locate cells 
expressing the GFP-PTEN proteins.  The objective lens was changed to 40x and the confocal 
mode was activated as well as 4x digital zoom was employed.  A 688 nm argon positive ion laser 
was used to excite the GFP.  A dichroic mirror that split the wavelength at 570 nm was used to 
send light <570 nm to the channel 1 detector (>570 to the channel 2 detector).  A barrier filter 
was used to allow only wavelengths of light in the range of 505 nm to 525 nm through to the 
detector.  GFP has an excitation wavelength of 488 nm and an emission wavelength of 509 nm. 
The focal plane was adjusted to the middle of the cell by performing quick low resolution scans 
at 1 micron intervals starting at the bottom of the cell and continuing through the top.  Middle 
layers of the cell were imaged using the Kalman scanning mode to take 5 consecutive scans of 
the same area and overlay them to reduce background and generate a clearer image.  All final 
images were the result of a 5 line-scan average combined using the FluoView software.  Adobe 
Photoshop v2.0 was used to adjust the levels of fluorescence intensity.   
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4.0 RESULTS 
 
Three aspects of PTEN were characterized.  First, PTEN activity was assayed in vitro and the 
ability of p85 to enhance PTEN lipid phosphatase activity was assessed.  Second, PTEN lipid 
binding specificity was examined utilizing lipid blots, which consisted of nitrocellulose 
membranes with purified lipids spotted onto them.  Finally, PTEN subcellular localization was 
studied in HEK293 cells using GFP-PTEN-C124S fusion proteins and visualized using confocal 
microscopy. 
 
4.1 PTEN phosphatase activity 
  
4.1.1 Characterization of PTEN phosphatase activity and the effect p85 had on that activity 
in vitro 
 
In order to investigate the effect of p85 on PTEN activity, a PTEN activity assay was first 
established.  A study of the enzymatic activity of PTEN required high quality and relatively pure 
protein.  The most efficient way to obtain bacterially-expressed protein of high purity was by 
using affinity chromatography.  PTEN was expressed and purified using a histidine tag 
consisting of six histidine residues fused to the N-terminus of the protein.  The histidine residues 
were captured using their affinity for nickel beads.  The His6-PTEN was eluted from the beads 
using imidazole.  A phosphatase-dead PTEN mutant (Cys 124 changed to Ser) was purified 
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similarly (His6-PTEN-C124S).  The purity of the His6PTEN preparations were verified after 
resolution by SDS-PAGE and Coomassie blue staining (Figure 4.1 a).  The immunoreactivity of 
each protein was confirmed by immunoblot analysis with anti-PTEN antibodies (Figure 4.1 b).  
To characterize the enzymatic activity of His6-PTEN in vitro, we used a fluorescently-labeled 
PTEN substrate, phosphatidylinositol 3,4,5-trisphosphate (PI3,4,5P3) (Taylor and Dixon, 2001).  
Briefly, 3 µg of His6-PTEN (final concentration of 3.18 µM) was incubated with 1.5 µg of 
fluorescently-tagged PI3,4,5P3 for 20 minutes to allow complete dephosphorylation of the 3' 
phosphate group.  Thin layer chromatography (TLC) was used to resolve the substrate, 
PI3,4,5P3, and product, phosphatidylinositol 4,5-bisphosphate (PI4,5P2), which were visualized 
using an ultraviolet transilluminator.   
Further experiments to assess both positive and negative effects of p85 on PTEN activity 
required the ability to detect increased or decreased PTEN activity.  Therefore, enzymatic 
activity was assayed at different concentrations of PTEN (Figure 4.1 c).  This titration of the 
PTEN enzyme allowed the selection of a lower concentration of PTEN (0.56 µM) to be used in 
subsequent assays with p85 to assess its regulatory effects.  The fluorescent PI3,4,5P3 substrate 
was not titrated because for quantification purposes, it was better to have the same amount of 
substrate in each lane on the TLC.  As a control, a known phosphatase-dead PTEN (PTEN-
C124S) was used to demonstrate lack of lipid phosphatase activity (Figure 4.1 c). 
Once titration of the concentration of PTEN was completed, the next step was to examine the 
effect of p85 on PTEN activity.  A His6-PTEN concentration of 0.56 µM was chosen since this 
converted approximately 40% of the PI3,4,5P3 substrate to PI4,5P2 product using the standard 
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Figure 4.1: Characterization of PTEN lipid phosphatase activity toward the substrate 
PI3,4,5P3 in vitro. (a-b) His6 tagged PTEN wild type (wt) and phosphatase dead (C124S) 
proteins were bacterially expressed and purified using affinity chromatography.  The proteins 
were resolved by SDS-PAGE stained with Coomassie blue (a) as well as transferred to 
nitrocellulose and probed with mouse anti-PTEN antibody conjugated to horseradish peroxidase. 
Visualization was accomplished using chemiluminesence (b). (c) The indicated concentrations of 
PTEN were assayed using a fluorescent PI3,4,5P3 lipid substrate.  The resulting product, PI4,5P2, 
was resolved from the PI3,4,5P3 substrate by TLC and then visualized under UV light (inset). 
Biorad Quantity One software was used to quantify the product using local background 
subtraction and normalization to the 0 PTEN lane  (the mean of three independent experiments is 
plotted and the bars represent the standard error of the mean). 
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assay conditions.  At this concentration of His6-PTEN, it would be apparent whether addition of 
p85 enhanced, inhibited or had no effect on His6-PTEN activity.  The p85 protein was expressed 
as a GST fusion protein, captured on glutathione Sepharose beads and cleaved from the GST 
using Thrombin protease (Figure 4.2 a).  The band that resolved at approximately 85 kDa was 
verified to be p85 by immunoblot analysis (Figure 4.2 b) 
To examine the quantitative effect that p85 had on His6-PTEN enzymatic activity in vitro, p85 
was added to the fluorescent PTEN enzyme assay at increasing concentrations (Figure 4.2 c).  
PTEN assay controls showed that the p85 preparation (1.12 µM) did not exhibit PTEN lipid 
phosphatase activity. Similar results were observed in a replicate experiment.  As the p85 
concentration increased, so did His6-PTEN activity to a maximum activation at a 1:1 molar ratio 
(0.56 µM for both p85 and PTEN).  Furthermore, the PTEN activation by p85 addition was 
approximately 3.5-fold when compared to the PTEN activity in the absence of p85.  These 
results clearly show that p85 can stimulate PTEN activity at least 3.5-fold in vitro, suggesting 
that p85 may be a positive regulator of PTEN.  
 
4.2 PTEN plasma membrane lipid binding 
 
4.2.1 PTEN proteins bound preferentially to phosphorylated phosphatidylinositol lipids 
 
PTEN has been proposed to remain in the cytoplasm and move to the membrane in response 
to some aspect of activation of PI3K signaling, such as growth factor stimulation (Cantley and 
Neel, 1999).   The ability of PTEN to bind to different lipids has not previously been examined, 
especially phosphatidylinositol phosphates.  In order to investigate PTEN binding specificity to a 
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Figure 4.2: PTEN dephosphorylation of PI3,4,5P3 is enhanced by the presence of p85 
protein.  His6-tagged PTEN fusion proteins were purified as stated previously.  The p85 protein 
was bacterially-expressed and purified as GST-p85.  Affinity chromatography was used to 
capture the GST tag.  The GST was cleaved from p85 using Thrombin protease. Proteins were 
resolved by SDS-PAGE stained with Coomassie blue (a) or transferred to nitrocellulose and 
probed with mouse anti p85-NSH2 antibody and visualized using chemiluminesence (b). (c) 
PTEN activity was assayed in the presence of increasing p85 concentrations (inset).  As controls, 
lipid, p85 (1.12 µM) and a high concentration of PTEN (3.18 µM; PTEN max) were also assayed 
individually and confirmed that the p85 preparation did not possess PTEN activity in the absence 
of added PTEN (inset).  Similar results were observed in a replicate experiment. 
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variety of plasma membrane lipids, we used purified His6-PTEN and His6-PTEN-C124S protein 
(Figure 4.1 a).  We hypothesized that the phosphatase-dead His6-PTEN-C124S mutant protein 
would be a substrate-trapping mutant and give a stronger, yet similar, binding profile to the wild 
type protein.  Also, in order to perform future experiments imaging PTEN localization in living 
cells, the C124S mutation would be required since enzymatically-active PTEN is rapidly 
degraded following translocation to the plasma membrane (Das et al., 2003).    
The His6-PTEN and His6-PTEN-C124S proteins were used to probe lipid blots in a fashion 
similar to immunoblotting (Figure 4.3 a).  After scanning using the Odyssey system, the supplied 
software was used to quantify the intensity of each spot.  The mean and standard error of the 
mean across three independent replicates was used to generate a bar graph to compare the 
binding profile of His6-PTEN to His6-PTEN-C124S (Figure 4.3 b).  A matched pairs t-test was 
used to determine the significance of difference.  The results indicated that the PTEN-C124S 
mutation did bind better to PI3P; PI4P; PI5P; PI3,4P2; PI3,5P2; PI4,5P2; PI3,4,5P3 and PA.  Both 
His6-PTEN and His6-PTEN-C124S proteins bound to phosphorylated PI lipids and PA but not to 
LPA, LPC, PE, PC, S1P and PS.  We wanted to determine if PTEN-C124S was in fact a 
substrate-trapping mutant, expected to bind better than, but to the same lipid targets as, the wild 
type PTEN.  To rule out that the C124S mutation resulted in a completely altered binding profile, 
the spot intensities in each set of replicates for each different protein were normalized to the 
PI4,5P2 spot and plotted on a bar graph (Figure 4.3 c).  Using a matched pairs t-test, it was 
determined that the PTEN-C124S binding profile was not significantly different than that of the 
wild type active PTEN (p < 0.01).  The normalized data was used for the t-tests with the 
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Figure 4.3: Wild type His6-PTEN and the phosphatase dead His6-PTEN-C124S both bind 
preferentially to phosphorylated PI lipids.  His6-PTEN and the enzymatic dead His6-PTEN-
C124S were bacterially expressed and purified as stated previously. (a)  Nitrocellulose 
membranes spotted with the indicated lipids (100 pmol/spot) were blocked for 1 h using 3% fatty 
acid free BSA in TBST.  The lipid blots were incubated with the indicated mutant PTEN 
proteins, washed and probed with mouse anti-PTEN(A2B1) primary antibody followed by goat 
anti-mouse secondary antibody conjugated to an infrared dye.  The blots were visualized using 
the Odyssey imaging system and the intensity of the individual spots was quantified using the 
Odyssey software v2.1.  (b)  Bars represent the mean intensity of three independent replicates 
and error bars are the standard error of the mean.  A matched pairs t-test was used to calculate 
significance of difference (* p<0.05; ¶ p<0.01).  (c)  Data was normalized to PI4,5P2 separately 
for each blot and analyzed as in panel b.  No significant differences in the lipid binding profile 
for wtPTEN and the C124S mutant were found (p<0.01).  LPA = lysophosphatidic acid; LPC = 
lysophosphocholine; PI = phosphatidylinositol; PI3P = phosphatidylinositol 3-phosphate; PI4P = 
phosphatidylinostiol 4-phosphate; PI5P = phosphatidylinositol 5-phosphate; PE= 
phosphatidylethanolamine; PC = phosphatidylcholine; S1P = sphingosine 1-phosphate; PI3,4P2 = 
phosphatidylinositol 3,4-bisphosphate; PI3,5P2 = phosphatidylinositol 3,5-bisphosphate; PI4,5P2 
= phosphatidylinositol 4,5-bisphosphate; PI3,4,5P3 = phosphatidylinositol 3,4,5-trisphosphate; 
PA = phosphatidic acid; PS = phosphatidylserine. 
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exception of the PI,45P2 spot intensities.  In this instance the raw data had to be used since it is 
not possible to compare two data sets with no variation.  Subsequent experiments generating 
additional mutations in PTEN also contained the C124S mutation since this modification was 
required in subsequent experiments for stable PTEN expression in mammalian cells.  These 
results confirm that the lipid binding specificities are not altered by the C124S mutation. 
 
4.2.2 Bacterially-expressed His6-PTEN-C124S mutants have altered binding to some 
membrane phosphatidylinositol phosphate lipids. 
 
Given the current state of knowledge about PTEN phosphorylation by casein kinase-2 
(Tolkacheva et al., 2001; Torres and Pulido, 2001; Vazquez et al., 2001; Vazquez et al., 2000) 
and the importance of the PASE and C2 domains in plasma membrane binding (Das et al., 2003) 
we strategically selected amino acids to be mutated to test the function of the proposed PTEN 
regulatory regions based on a published partial crystal structure of PTEN (Lee et al., 1999).  
Two types of mutations were made involving either phosphorylation sites or clusters of 
positively-charged basic amino acids.  Phosphorylation sites were altered to mimic the 
phosphorylated state and dephosphorylated state by substitution of the regulatory 
phosphorylation sites with glutamate or alanine, respectively.  Clusters of positive charge were 
removed by substituting basic amino acid residues in these clusters with alanine.  Seven distinct 
His6-PTEN-C124S mutants were generated (Table 4.1).   Two regulatory casein kinase 2 
phosphorylation site mutations were created to mimic the phosphorylated and dephosphorylated 
states. These distinct mutants involved substitution of basic residues in the C2 and PASE 
domains to disrupt positively charged surfaces.  Finally, tyrosine 336 was altered to mimic both 
phosphorylated and non-phosphorylated states.   
  64 
Table 4.1 Histidine tagged PTEN-C124S mutants 
Mutant Name Amino Acids Mutated 
His6-PTEN-C124S-STT/AAA S380A/T382A/T383A 
His6-PTEN-C124S-STT/EEE S380E/T382E/T383E 
His6-PTEN-C124S-PASE-RKK/AAA R161A/K163A/K164A 
His6-PTEN-C124S-C2-K5/A K260A/K263A/K266A/K267A/K269A 
His6-PTEN-C124S-C2-K3/A K327A/K330A/K332A 
His6-PTEN-C124S-Y336A Y336A 
His6-PTEN-C124S-Y336E Y336E 
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The serine and threonine residues within the regulatory domain are S380, T382 and T383 and 
are phosphorylated by casein kinase 2.  Site-directed mutagenesis was used to alter these 
phosphorylation sites to mimic either a constitutive dephosphorylated state, STT/AAA, or 
constitutive phosphorylated state, STT/EEE.  The STT/AAA mutant has been shown to 
constitutively localize to the plasma membrane independent of growth factor treatment (Das et 
al., 2003).   
Clusters of basic amino acid residues in the PASE and C2 domains impart regions of positive 
charge, which are important for plasma membrane localization.  The mutations made in the 
PASE and C2 domains were selected to neutralize these regions of positive charge to test their 
proposed role in binding to the plasma membrane via non-specific electrostatic interactions.  One 
group of positive amino acid residues was located in the PASE domain.  The C2 domain 
contains an N-terminal cluster of five basic amino acids and a C-terminal cluster of three basic 
amino acids.  The PASE group of amino acid residues included R161, K163 and K164.  The N-
terminal cluster of positive amino acids mutated in the C2 domain were five lysines located at 
residues 260, 263, 266, 267 and 269 and the C-terminal lysines substituted by alanine were 
located at residues 327, 330 and 332.  Furthermore, the partial crystal structure PTEN revealed 
that all eleven of these residues are located on the same surface, consistent with their suggested  
role in plasma membrane binding (Lee et al., 1999).  PTEN has 23 tyrosine residues located 
within consensus sequences for phosphorylation, leading to speculation that tyrosine 
phosphorylation may be an important modifier of PTEN behavior (Lu et al., 2003).  Difficulty 
arises when trying to study phosphorylation of a phosphatase such as PTEN because it is also a 
protein tyrosine phosphatase.  Thus it may be capable of autodephosphorylation in the absence 
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of other proteins.  Some studies have mutated PTEN tyrosine residues to characterize what, if 
any, regulatory effects a particular tyrosine may have in cells (Miller et al., 2002).  Of particular 
interest was the tyrosine at position 336, which is located within the clusters of basic residues in 
the C2 domain.  Phosphorylation of this residue could have an important role in regulating PTEN 
plasma membrane localization.  Mutations of the tyrosine at position 336 had been previously 
generated to change the residue to an alanine or a glutamate to mimic unphosphorylated or 
phosphorylated states, respectively.  
The PTEN-C124S mutant proteins were expressed and purified under my supervision by S. 
Knafelc (Summer Student, 2006) (Figure 4.4 a-b).   The His6-PTEN C124S mutants were used to 
probe lipid blots as stated previously.  The blots were scanned using the Odyssey imaging 
system (figure 4.4 c).  The results indicated that the His6-PTEN-C124S mutant proteins as well 
as the control His6-PTEN-C124S protein do not bind to non-phosphatidylinositol phospholipids 
with significant intensity.  This is same result obtained previously for the His6-PTEN wt and 
His6-PTEN-C124S proteins (Figure 4.2).  Therefore, in the subsequent data analysis these values 
were not included.  Phosphatidylinositol was included because it is the precursor molecule to all 
the phosphorylated PI molecules and phosphatidic acid was also included because some 
significant differences were observed (Figure 4.5).  
The His6-PTEN-C124S-STT/AAA protein had no significant differences in lipid binding 
preference when compared to the bacterially-expressed control His6-PTEN-C124S.  The His6-
PTEN-C124S-STT/EEE mutant demonstrated some slightly impaired binding to the PI, PI4P, 
PI3,4P2, and PA lipids.  His6-PTEN-C124S-PASE-RKK/AAA had significantly impaired  
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Figure 4.4: His6-PTEN-C124S mutants have altered binding to specific membrane lipids.  
The data shown in panels a and b was generated by S. Knafelc under my supervision. (a)  His6-
PTEN-C124S mutant proteins were bacterially-expressed and purified using Talon beads.  The 
His6-PTEN-C124S mutant proteins were resolved by SDS-PAGE (10%) and stained with 
Coomassie blue.  (b) Proteins were resolved by SDS-PAGE and transferred to nitrocellulose.  
The nitrocellulose blots were probed with a mouse anti-PTEN horseradish peroxidase-conjugated 
antibody and visualized by chemiluminescence.  (c)  Nitrocellulose membranes containing the 
indicated lipids (100 pmol/spot) were blocked and probed with the indicated His6-PTEN-C124S 
mutants .  Bound proteins were detected using mouse anti-PTEN antibodies, followed by rabbit 
anti-mouse antibodies conjugated with a infrared tag and were visualized simultaneously with 
the Odyssey imaging system (LI-COR IRDYE-680, n=4). LPA = lysophosphatidic acid; LPC = 
lysophosphocholine; PI = phosphatidylinositol; PI3P = phosphatidylinositol 3-phosphate; PI4P = 
phosphatidylinostiol 4-phosphate; PI5P = phosphatidylinositol 5-phosphate; PE= 
phosphatidylethanolamine; PC = phosphatidylcholine; S1P = sphingosine 1-phosphate; PI3,4P2 = 
phosphatidylinositol 3,4-bisphosphate; PI3,5P2 = phosphatidylinositol 3,5-bisphosphate; PI4,5P2 
= phosphatidylinositol 4,5-bisphosphate; PI3,4,5P3 = phosphatidylinositol 3,4,5-trisphosphate; 
PA = phosphatidic acid; PS = phosphatidylserine.   
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binding to all lipids with the exception of PI4P and PA.  Both C2 domain mutants, His6-PTEN-
C124S-C2-K5A and His6-PTEN-C124S-C2-K3A, had significantly impaired binding to all 
lipids.  His6-PTEN-C124S-Y336A had little difference in binding except for slightly less binding 
to PI and PA.  The His6-PTEN-C124S-Y336E displayed significantly reduced binding to PI4P, 
PI3,5P2, PI4,5P2, PI3,4,5P3 and PA.  This suggests that a negative charge at this residue within 
the positively charged C2 domain surface interferes somewhat with PTEN binding to specific 
lipids. 
 
4.3 PTEN cellular localization 
 
4.3.1 PTEN cellular localization in response to epidermal growth factor stimulation 
 
In order to assess PTEN subcellular localization, each PTEN mutant was expressed as an 
enhanced green fluorescent protein (eGFP) fusion protein.  Since active PTEN is quickly 
degraded after translocation to the plasma membrane (Das et al., 2003), it was necessary to use 
the phosphatase-dead C124S versions of these mutants in order to capture images using a 
scanning laser confocal microscope.  
Although GFP-PTEN-C124S fusion proteins have been expressed and imaged in cells 
previously, no one had examined the effect of growth factor stimulation on PTEN localization.  
One previous report clearly demonstrated that removal of the casein kinase 2 phosphorylation 
sites in the regulatory domain (S380, T382 and T383) by mutation to alanine or deletion resulted 
in a GFP-PTEN-C124S mutant that was constitutively localized to the plasma membrane (Das et 
al., 2003).  Since we hypothesized that PTEN moves to the plasma membrane upon growth 
factor stimulation, the PTEN-C124S-STT/AAA mutant was an ideal control for a plasma 
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membrane localized protein.  GFP-PTEN-C124S or GFP-PTEN-C124S-STT/AAA were 
visualized in the context of regular versus EGF stimulated conditions (Figure 4.6 a) The images 
generated confirmed that GFP-PTEN-C124S does appear to become less cytoplasmic and more 
concentrated at the plasma membrane upon growth factor stimulation (Figure 4.6 b). 
 
4.3.2 Importance of Positive Charge for PTEN Subcellular Localization 
  
Mutants had already been generated and bacterially-expressed, previously in the laboratory, as 
recombinant proteins for use in lipid binding assays.  Some of the same mutants were expressed 
in a mammalian system using the pEGFP mammalian expression vector.  Of particular interest 
were the PTEN-C124S mutants that had seriously altered binding to lipids as observed in the 
lipid binding experiments; these were: PTEN-C124S-PASE-RKK/AAA, PTEN-C124S-C2-K5A 
and PTEN-C124S-C2-K3A.  PTEN-C124S-STT/EEE was also tested.  Unfortunately, the GFP- 
PTEN-C124S-C2-K5A plasmid did not express well and no images were acquired.  Similar 
experiments to the GFP-PTEN-C124S subcellular localization experiment in Figure 4.6 were 
performed.  This set of experiments gave us an opportunity to test the mutants in the context of a 
mammalian system capable of performing posttranslational modifications and regulation, 
including phosphorylation events.  
The mutants examined, C2-K3A, PASE RKK/AAA and STT/EEE, did not show definitive 
membrane localization upon growth factor stimulation (Figure 4.6 c-e).   In all three instances, 
the experimental cell (growth factor treated) appeared similar in size, shape and GFP dispersion 
compared to the control cell (no growth factor).  In no instance did the growth factor treated cells 
resemble the plasma membrane localization control GFP-PTEN-C124S-STT/AAA. These results 
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Figure 4.6: Confocal micrographs of GFP-PTEN-C124S mutant proteins.  Plasmids 
encoding GFP-PTEN-C124S fusion proteins were transiently transfected into HEK293 cells 
seeded onto coverslips and allowed to grow for 24 h.  Treatment with EGF (5 min) was 
performed as indicated and the cells were fixed and mounted to slides.  Visualization was 
performed using confocal microscopy and sizing bars represent 10 microns.  (a) GFP-PTEN-
C124S-STT/AAA constitutively localizes to the plasma membrane and thus was a positive 
control for plasma membrane localization. (b-e) Plasmids encoding the indicated GFP-PTEN-
C124S and GFP-PTEN-C124S mutants were treated as above and stimulated with growth factor 
as indicated.  Scale bar = 10 µm.                          
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suggested that the positive charge imparted by clusters of basic amino acids in the PASE and C2 
domains were required for the plasma membrane localization of PTEN in response to EGF 
stimulation. 
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5.0 DISCUSSION 
 
5.1 PTEN structure/function studies 
 
5.1.1 Phosphorylation of PTEN 
  
A complete understanding of PTEN regulation is still under investigation.  Regulation of 
PTEN levels have been linked to ubiquitination by the ubiquitin ligase neural precursor cell 
expressed, developmentally downregulated-4-1 (NEDD4-1) (Wang et al., 2007).  NEDD4-1 
polyubiquitinates PTEN, resulting in ubiquitin-mediated proteasomal degradation (Wang et al., 
2007).  Acetylation of PTEN by the histone acetyltransferase p300/CBP-associated factor 
(PCAF), decreased PTEN lipid phosphatase activity (Okumura et al., 2006).  Acetylation and 
ubiquitination have not been implicated in the open/closed conformation of PTEN.  Regulation 
via phosphorylation is the most relevant with regard to our previous studies of EGFR signaling, 
open/closed conformation model, and relevance to the pathogenesis of cancer (Das et al., 2003; 
Torres and Pulido, 2001).  Several phosphorylation sites have been identified within PTEN that 
contain serines, threonines or tyrosines (Miller et al., 2002).  Casein kinase 2 has been shown to 
phosphorylate PTEN at five specific sites in the regulatory domain in a hierarchical fashion, with 
the primary sites being Ser370 and Ser385 followed by Ser380, Thr382 and Thr383 (Torres and 
Pulido, 2001).  It has been demonstrated that phosphorylation of Ser370 and Ser385 inhibits both 
the lipid phosphatase activity and caspase-dependent proteosomal degradation of PTEN (Miller 
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et al., 2002; Torres and Pulido, 2001).  This finding suggests that PTEN is stabilized when it is 
inactivated since only active PTEN can be degraded.  Investigation of the last three casein kinase 
2 phosphorylation sites led to the discovery that these sites are important for the regulation of the 
plasma membrane localization of PTEN.  Removal of the regulatory domain (aa 353-403) or 
even mutation of residues 380, 382 and 383 to alanine (PTEN-C124S-STT/AAA) resulted in 
constitutive plasma membrane localization (Das et al., 2003).  The same effect could not be 
observed with active PTEN because after translocation to the plasma membrane PTENwt is 
rapidly degraded (Das et al., 2003).  This data, along with the crystal structure of PTEN, helped 
develop the open/closed conformation model of PTEN regulation (Das et al., 2003; Lee et al., 
1999).   
It has been proposed that when phosphorylated in the regulatory domain, PTEN adopts a 
closed conformation.  The regulatory domain is folded over and interacts with clusters of 
positive charges in the PASE and C2 domains.  The closed conformation of PTEN is localized to 
the cytosol (Figure 5.1).  PTEN adopts the open conformation in response to dephosphorylation 
of the casein kinase 2 sites in the regulatory domain.  The PASE and C2 regions are unmasked as 
the interaction with the regulatory domain is disrupted. 
We substituted the regulatory domain phosphorylation sites with alanine (PTEN-C124S-
STT/AAA) or glutamic acid (PTEN-C124S-STT/EEE).  We wanted to test if these mutations 
altered the preference for selected plasma membrane lipids.  The plasma membrane lipids that 
were chosen included a variety of phosphorylated phosphatidylinositol lipids.  Since the His6- 
PTEN-C124S protein was bacterially-expressed and purified, it contained none of the post- 
translational modifications, such as phosphorylation, found in cells and had indistinguishable 
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Figure 5.1: Depictions of the PTEN-C124S mutants in their respective open/closed 
conformation in unstimulated and EGF-stimulated conditions. (a) PTEN-C124S is closed 
and cytoplasmic in unstimulated cells.  Upon EGFR activation PTEN adopts the open 
conformation. (b) PTEN-C124S-STT/AAA has the casein kinase 2 phosphorylation sites 
changed to alanine and is constitutively open and plasma membrane (PM) localized regardless of 
EGFR status. (c) PTEN-C124S-STT/EEE is a mimic of constitutive casein kinase 2 
phosphorylation and always in the closed conformation and restricted to the cytoplasm. (d) 
Mutation of the clusters of positive charge in the PTEN-C124S-PASE-RKK/AAA, PTEN-
C124S-C2-K5A, and PTEN-C124S-C2-K3A results in open conformation PTEN that does not 
localize to the plasma membrane, but is still phosphorylated by casein kinase 2. 
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lipid binding preference compared to the His6-PTEN-C124S-STT/AAA mutant protein.  The 
His6-PTEN-C124S-STT/EEE mutant had a similar lipid binding profile to the His6-PTEN-C124S 
protein.  There were statistically significant decreases in lipid binding preference towards the PI, 
PI4P, and PI3,4P2 lipids.  Although there was a statistical difference between the His6-PTEN-
C124S-STT/EEE and His6-PTEN-C124S proteins, the general characteristics of the data show a 
very similar profile.  This suggests that in the context of bacterially-expressed recombinant 
proteins the casein kinase 2 phosphorylation sites do not greatly alter binding preference to the 
lipids tested. 
We expressed the same mutants in HEK293 cells as GFP fusion proteins to assess the effects 
of the mutations in the context of growth factor stimulation.  The GFP-PTEN-C124S-STT/AAA 
mutant had been previously established to constitutively localize to the plasma membrane and 
was used as a positive control for plasma membrane localization (Das et al., 2003).  In quiescent 
cells, the GFP-PTEN-C124S protein was cytoplasmic and upon stimulation with EGF, it 
translocated to the plasma membrane.  According to our hypothesis, the GFP-PTEN-C124S-
STT/EEE mutant would remain in the cytoplasm in a closed conformation regardless of growth 
factor stimulation.  The results observed were consistent with our hypothesis.  The GFP-PTEN-
C124S-STT/EEE mutant was cytoplasmic in both the unstimulated and EGF-stimulated cells.  
Previous evidence demonstrated that casein kinase 2 phosphorylation of PTEN serves to inhibit 
lipid phosphatase activity and stabilize the protein (Torres and Pulido, 2001).  Our data suggests 
a second function for casein kinase 2 phosphorylation, that being to restrict PTEN to the 
cytoplasm.  Preliminary phosphatase activity experiments performed in vitro with purified 
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protein generated data that has shown PTEN-STT/EEE retains phosphatase activity, suggesting 
that phosphorylation at these sites regulates PTEN plasma membrane localization via 
open/closed conformation and not intrinsic PTEN lipid phosphatase enzymatic activity (S. 
Knafelc, unpublished observations). 
Upon examination of the partial crystal structure of PTEN, we also identified a tyrosine 
residue within the C2 domain.  The tyrosine is located at position 336 and its orientation in the 
three dimensional structure placed it on the same surface of the protein as several clusters of 
positively charged amino acids.  Using site-directed mutagenesis, we generated a 
dephosphorylation and phosphorylation mimic by mutating Tyr336 to Ala and Glu, respectively.  
The two mutants generated, His6-PTEN-C124S-Y336A and His6-PTEN-C124S-Y336E, were 
tested for lipid binding preferences and compared to the His6-PTEN-C124S control protein as 
described earlier.  The Y336A mutant displayed some slightly decreased preference for binding 
to the PI lipid, but otherwise exhibited no significant difference from the control.  The His6-
PTEN-C124S-Y336E mutant had statistically significant decreased binding to the PI3P, PI4P, 
PI4,5P2, PI3,4,5P3 and PA lipids, suggesting that the extra negative charge imparted by the 
glutamate did interfere with lipid binding.  Note that the Y336E mutation decreased binding to 
both the substrate (PI3,4,5P3) and product (PI4,5P2) of PTEN, suggesting that if this site were 
phosphorylated it could attenuate PTEN function.  These data suggest that Y336 has the potential 
to be a regulatory site for PTEN since if it was phosphorylated, PTEN lipid binding would be 
impaired.  Since an actual phosphate group at this position imparts a greater negative charge than 
a glutamate, the decreased binding may be even more marked.  It is tempting to speculate that 
this is the mechanism by which PTEN is disengaged from the plasma membrane (Figure 5.2). 
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Figure 5.2: Proposed models of PTEN-C124S-Y336 mutants’ open/closed conformation in 
unstimulated and EGF stimulated conditions. (a) PTEN-C124S-Y336A is closed and 
cytoplasmic in unstimulated cells.  Upon EGFR activation PTEN adopts the open conformation 
and can translocate to the plasma membrane (PM). (b) PTEN-C124S-Y336E is open, but 
cytoplasmic in both unstimulated and stimulated cells.  (c) Our proposed regulatory feature for 
Y336 is that it may be phosphorylated by an RTK, thus disengaging PTEN from the PM. 
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However, whether Y336 is phosphorylated in cells has yet to be determined.  
  
5.1.2 The role of basic amino acid residues in plasma membrane targeting 
 
The model of PTEN open and closed conformations proposes that the regulatory domain, 
when phosphorylated, is involved in masking positively charged surfaces in the PASE and C2 
domains.  Upon dephosphorylation, PTEN adopts the open conformation and is capable of an 
electrostatic interaction with the plasma membrane.  C2 domain-containing proteins are typically 
involved in membrane binding, however the C2 domain of PTEN has been shown to be 
insufficient to result in plasma membrane localization (Das et al., 2003).  A cluster of basic 
amino acids in the PASE domain (R161/K163/R164) were previously tested for involvement in 
plasma membrane targeting (Das et al., 2003).  It was observed that when the positive charge of 
this cluster was neutralized (PASE-RKK/AAA), the affinity for anionic lipid vesicles was greatly 
reduced.  In addition, a PTEN-PASE-RKK/AAA mutant that also lacked the regulatory domain 
was localized to the cytoplasm of HEK293 cells, consistent with the proposed role of the basic 
residues in plasma membrane association (Das et al., 2003).  From the partial crystal structure of 
PTEN, there are two other clusters of positive charge located in the C2 domain on the same 
surface as the PASE domain cluster (Lee et al., 1999).  Lee and colleagues (1999) mutated a 
series of residues in the C2 domain.  The residues mutated were 263-K-M-L-K-K-D-K-269 to 
263-A-A-G-A-A-D-A-269 and 327-K-A-N-K-D-K-A-N-335 to 327-A-A-G-A-D-A-A-N-A-335.  
They observed decreased affinity for PC lipid vesicles with these two mutants.  When expressed 
in cells, these same mutants also displayed a phenotype similar to cells derived from PTEN 
mutant L345G tumors (Lee et al., 1999).  The tumor phenotype was characterized by increased 
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proliferation and decreased contact inhibition compared to wild type PTEN-expressing cells (Lee 
et al., 1999).  Since PTEN had been previously tested for binding to plasma membrane 
mimicking anionic lipid vesicles POPC and POPS, we wanted to test the PTEN-C124S-PASE-
RKK/AAA mutant as well as the PTEN-C124S-C2-K5A and PTEN-C124S-C2-K3A mutants for 
their ability to bind a broader range of membrane lipids including phosphatidylinositol lipids.  
The His6-PTEN-C124S-PASE-RKK/AAA, His6-PTEN-C124S-C2-K5A and His6-PTEN-C124S-
C2-K3A mutants were compared to the His6-PTEN-C124S control protein using the lipid blots.  
All three mutants showed severely impaired lipid binding ability compared to His6-PTEN-
C124S.  The PTEN-PASE-RKK mutant had previously been tested for lipid phosphatase activity 
and was found to retain activity (Das et al., 2003).  Preliminary data have demonstrated that the 
His6-PTEN-C2-K5A and His6-PTEN-C2-K3A mutants do not have lipid phosphatase activity (S. 
Knafelc, unpublished observations).  This further illustrated that the PASE and C2 domains are 
both important for functional lipid phosphatase activity and lipid binding.  Although the mutants 
did not display lipid phosphatase activity, it is important to note that they were expressed at 
similar levels to the other PTEN proteins in bacteria and were soluble.  This suggests that the 
decreased lipid binding were not a result of poorly folded protein.  Further investigation of the 
mutant proteins could be obtained by using circular dichroism measurements and/or limited 
trypsin digestion to verify they are properly folded proteins.  
The three mutants were also expressed as GFP-fusion proteins in HEK293 cells and their 
localization within the cell was visualized before and after treatment with EGF using confocal 
microscopy.  The ability of the GFP-PTEN-C124S-PASE-RKK/AAA and the GFP-PTEN-
C124S-C2-K3A mutants to localize to the plasma membrane in response to EGF stimulation was 
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impaired.  This result is consistent with the model that the clusters of positive charge in these 
domains are required for lipid binding and targeting to the plasma membrane.    
The GFP-PTEN-C124S-C2-K5A mutant was poorly expressed in the HEK293 cells.  This 
mutant may be quickly degraded in cells.  The reason for this could be that the regulatory casein 
kinase 2 sites are still present even though a significant amount of positively charged residues 
have been substituted for alanine.  When the casein kinase 2 sites are phosphorylated, these three 
phosphate groups likely interact with the positive charge cluster in the C2 domain.  Since the 
PTEN-C124S-C2-K5A mutant lacks this positive charge cluster, there may be insufficient 
electrostatic forces to facilitate an intramolecular interaction between the C2 domain and the 
regulatory domain.  Thus, the protein may not adopt the closed conformation.  PTEN that is 
phosphorylated at the casein kinase 2 sites and in an open conformation in the cytoplasm, may be 
unstable.  Another possibility for the poor expression of GFP-PTEN-C124S-C2-K5A in cells, is 
that there are simply too many mutations to express a properly folded protein.  Although the 
PTEN-C124S-C2-K5A was expressed and purified as a soluble recombinant protein in bacteria, 
posttranslational modifications that occur in a mammalian cell system may affect protein 
stability.  
The open/closed conformation model for PTEN proposes that PTEN in the open conformation 
localizes to the plasma membrane.  The PASE domain mutations as well as the C2-K3A 
mutations resulted in mutant proteins that failed to localize to the plasma membrane upon growth 
factor stimulation.  Thus the data generated are consistent with the current model.  
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5.2  PTEN and p85 
 
PTEN was originally cloned in 1997 and over the past decade a large body of evidence has 
been compiled linking the PTEN phosphatase with tumor suppression.  Although PTEN is a dual 
specificity phosphatase, possessing both protein phosphatase and 3' phosphoinositide 
phosphatase activity, it is only the latter function that has been linked to tumor suppression (Wu 
et al., 2003).  PTEN attenuates the PI3K/Akt signaling pathway, which is activated in response 
to growth factor activation.  When a growth factor, such as EGF, binds to its receptor, 
autophosphorylation of tyrosine residues creates docking sites for SH2 domain-containing 
proteins.  The regulatory subunit of PI3K, p85, contains two SH2 domains that allow it to recruit 
the catalytic subunit, p110, to the plasma membrane in response to EGFR activation.  PI3K 
catalyzes the phosphorylation of PI4,5P2 to PI3,4,5P3.  The lipid second messenger PI3,4,5P3 
interacts with the PH domains of Akt and PDK1, promoting the activation of Akt by PDK1 via 
phosphorylation.  PTEN antagonizes PI3K/Akt signaling by removal of the 3' phosphate from 
the second messenger PI3,4,5P3.  A decrease in the cellular concentration of PI3,4,5P3 results in 
less Akt and PDK1 at the plasma membrane.  This allows cells to undergo apoptosis or exit the 
cell cycle. 
PTEN and p85:p110 are known to carry out opposing functions in RTK signaling.  The p85 
protein is involved in the activation of the PI3K/Akt pathway whereas the PTEN protein 
deactivates this pathway.  Experimental evidence now suggests a more integrated regulation of 
p110-PI3K and PTEN.  The two enzymes and their opposing forces on opposite sides of a 
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molecular switch are connected by the p85 protein.  Our laboratory previously identified that p85 
and PTEN interact and that p85 enhances PTEN enzymatic activity in vitro (Chagpar, 2004).  
Another laboratory observed that PTEN and p85 can be isolated from tissues with the scaffolding 
protein MAGI-2 in a multi-protein complex termed the PTEN-associated complex (PAC) (Wu et 
al., 2000a).  This suggested that p85 and PTEN may have an interconnected function in cells.  
Increased epithelial transformation has been frequently observed in PTEN (+/-) mice (Di 
Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998).  PTEN (+/-) mice that also 
have half the normal expression of Pik3r1 (p85α, p55α, p50α) displayed increased intestinal 
polyp incidence (~2-fold) and number (>3-fold) compared with PTEN (+/-) mice.  This suggests 
that p85 has a role in tumor suppression, at least under conditions of reduced PTEN expression 
(Luo et al., 2005). 
Based on the evidence generated by Ryaz Chagpar in our laboratory, combined with the 
collective knowledge of the literature, we decided to directly investigate the nature of the PTEN 
and p85 interaction.  Others in the laboratory performed GST pulldown experiments and 
demonstrated that GST-PTEN-C124S binds to p85.  Using lysates containing espressed p85 
domains, D. Anderson observed that a region within the BH domain of p85 facilitates binding to 
PTEN.  As described in section 4.1, a PTEN lipid phosphatase assay was modified to assess the 
activation of PTEN by p85.  The p85 protein was added in increasing concentration and the 
maximum activation observed was at a 1:1 molar ratio of p85:PTEN.  A 3.5-fold activation was 
observed at this molar ratio.  The p85 protein was also assayed independently of PTEN as a 
control to demonstrate that p85 alone does not alter the lipid substrate.   
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PTEN binds the MAGI-2 protein at the PDZ-2 domain (Tolkacheva et al., 2001).  This 
interaction has been demonstrated to be biologically relevant as expression of MAGI-2 enhances 
PTEN signaling, but has no effect in the presence of a PTEN mutant unable to bind MAGI-2 
(Wu et al., 2000a).  The nature of p85 involvement with MAGI-2 is not yet characterized.  
However, MAGI-2 contains two WW domains, which bind proline-rich regions (Wu et al., 
2000b).  The p85 protein has two regions on either side of the BH domain that are rich in proline 
residues.  We hypothesize that p85 interacts with the two WW domains of MAGI-2 via these 
proline sequences (Figure 5.3).  MAGI-2 and p85 are both cytoplasmic proteins that translocate 
to the plasma membrane in response to activated RTKs, such as the EGFR (Klippel et al., 1993; 
Xu et al., 2001).  The PTEN-associated complex (PAC)  has been isolated at the plasma 
membrane (Vazquez et al., 2001).  The current model of p85/PTEN interaction in cells is that 
MAGI-2, p85 and PTEN are recruited to the plasma membrane independently of each other upon 
RTK activation.  Once at the plasma membrane, PTEN, p85 and possibly other proteins, such as 
RTKs, bind to the scaffolding protein MAGI-2.  We hypothesize that MAGI-2 binding serves 
two key functions.  First, it facilitates enhancement of PTEN activity by p85.  Second, it targets 
PTEN to the activated EGFR where its substrate is being produced by PI3K.  We hypothesize 
that an interaction occurs between a PDZ binding domain within MAGI-2 (a component of the 
PAC) and a PDZ binding motif at the C-terminus of the EGFR.  This would localize PTEN to 
the site where PI3K is actively generating PI3,4,5P3 second messengers.  The data in this thesis 
using the Y336E mutant of PTEN further suggests a possible mechanism by which PTEN is 
disengaged from the plasma membrane.  Phosphorylation of PTEN Y336, by an RTK, may  
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Figure 5.3: Proposed model for the interaction between the PTEN, p85 and MAGI-2 
proteins in the PTEN-associated complex.  A PTEN-associated complex (PAC) has been 
isolated from tissue extracts containing PTEN, p85 and MAGI-2.  MAGI-2 is a scaffolding 
protein that is cytosolic in quiescent cells, but translocates to the plasma membrane upon growth 
factor stimulation.  MAGI-2 has 6 PDZ domains.  PTEN is known to bind to the PDZ2 domain 
of MAGI-2.  It is possible that p85 binds to one or both WW domains via proline-rich regions. 
MAGI-2 may interact with a PDZ binding motif of the activated receptor. MAGI-2 also has a 
guanylate kinase-like (Guk) domain that is catalytically inactive.    
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release PTEN from the plasma membrane once PI3K signaling has been terminated. 
 
5.3 Future directions  
 
The next step in the analysis of PTEN is to examine if phosphorylation at position Y336 is 
biologically relevant.  Tandem mass spectrometry could identify if Y336 is a phosphorylation 
site on PTEN and if it is phosphorylated in the presence or absence of EGF.  Antibodies specific 
for PTEN phosphorylated on Y336 could be used to probe whole cell lysates generated at 
various time points during EGF stimulation.  This would determine if the cellular concentration 
of PTEN-Y336-phosphorylated changes over the course of EGF stimulation.  Confocal 
microscopy experiments using the PTEN mutants GFP-PTEN-C124S-Y336A and GFP-PTEN-
C124S-Y336E in cells in the context of growth factor stimulation would be performed to 
examine if there is altered plasma membrane localization upon growth factor stimulation.  These 
experiments may provide some insight into Y336 as a possible regulatory site for plasma 
membrane delocalization if the Y336E mutation impairs membrane localization upon growth 
factor stimulation.  Since confocal microscopy generates qualitative data, some quantitative 
results to corroborate the images are required.  The PTEN-C124S-Y336A and PTEN-C124S-
Y336E mutants can be bacterially-expressed as recombinant proteins and be tested for their 
affinity to select membrane phosphatidylinositol phosphate lipids using a surface plasmon 
resonance (Biacore) system.  These experiments will provide direct measurements of the affinity 
of these mutants for selected membrane lipids.  Further testing of the Y336 mutants will involve 
phosphatase active versions (PTEN-Y336A and PTEN-Y336E) of the mutants that can be 
expressed in bacteria, purified and assayed for lipid phosphatase activity.  This experiment 
compares the activity of the unphosphorylated and phosphorylated mimics to examine if the 
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Y336 residue has a role in the regulation of intrinsic lipid phosphatase activity.  In order to 
examine the effects of the Y336 mutants that mimic constitutive unphosphorylated and 
phosphorylated states in cells, these PTEN mutants will be overexpressed, whole cell lysates 
generated, and immunoblot analysis implemented to compare phosphorylated Akt levels.  The 
PTEN-Y336A mutant may result in lower phosphorylated Akt levels due to increased PTEN 
signaling relative to the PTEN-Y336E mutant.   
It has been established that PTEN binds to p85 as well as MAGI-2.  To map the region of 
PTEN that binds to p85, regions of PTEN expressed as GST fusion proteins can be used in GST 
pulldown experiments with whole cell lysates as a source of p85 protein.  This information can 
be used to generate a PTEN mutant incapable of binding to p85 (PTEN∆p85).  PTEN interacts 
with the PDZ2 domain of MAGI-2 via a PDZ binding motif.  Two additional PTEN mutants can 
also be generated that are incapable of binding MAGI-2 (i.e. PTEN without its PDZ binding 
motif - PTEN∆MAGI-2) and a double mutant that does not interact with p85 and MAGI-2 
(PTEN∆p85-MAGI-2).  These three PTEN mutants can be assayed in vitro for lipid phosphatase 
activity to confirm that they are properly folded, functional proteins.  Each can also be expressed 
as GFP fusion proteins and their ability to translocate to the plasma membrane upon growth 
factor stimulation can be assessed in HEK293 cells.  This experiment will test the current model 
that PTEN non-specifically localizes to the plasma membrane upon receptor activation 
independently of MAGI-2 and/or p85.  Each mutant may also be expressed individually and 
phosphorylated Akt levels can be compared quite accurately using the Odyssey imaging system 
for quantitative western blot analyses.  If our model is correct, then the levels of phosphorylated 
Akt will be lower for PTEN∆p85, PTEN∆MAGI-2, and PTEN∆p85-MAGI-2 versus PTENwt.  
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Some comparisons may also be drawn between phosphorylated Akt levels among the three 
mutants as well. 
PI3K is recruited to activated receptors upon growth factor stimulation by the SH2 domains of 
p85, where the p110 subunit generates the PI3,4,5P3 product.  Our model proposes that MAGI-2 
targets PTEN to this PI3,4,5P3 substrate by simultaneously interacting with PDZ binding motifs 
on PTEN (known) as well as the receptor.  In order to test this model in cells, the MAGI-2 
protein can be expressed as a red fluorescent protein (RFP) fusion protein, and using fluorescent 
dye conjugated anti-EGFR antibodies, we can assess whether MAGI-2 and EGFR are co-
localized in EGF-stimulated cells.  Furthermore, we can express both RFP-MAGI-2 and GFP-
PTEN-C124S to examine if the two proteins are co-localized in quiescent cells as well as in 
response to growth factor stimulation.  Since fluorescence microscopy is not sufficient to make 
convincing arguments about the interaction of PTEN and MAGI-2 in cells, co-
immunoprecipitations can be performed with the wild type proteins as well as with non-binding 
mutants to complement the microscopy data. 
 
5.4 Conclusion 
 
Mapping of homozygous deletions on human chromosome 10q23 led to the isolation of the 
PTEN gene in 1997 as a candidate tumor suppressor (Steck et al., 1997).  Since its discovery, it 
has been identified as an important tumor suppressor and its characteristics and biological 
function have been well-studied.  The lipid phosphatase activity of PTEN has been established as 
the key attenuator of the PI3K/Akt pathway.   
  89 
Although the function of PTEN has been known for some time now, insight into regulation of 
this important protein is only now emerging.  Our laboratory, through the study of the 
Ras/Raf/MAPK pathway and the role of p85, discovered that PTEN enzymatic activity is 
enhanced by p85.  Although the work in this thesis is not comprehensive, the characterization of 
PTEN activity in the presence of p85 has given further insight into p85 being the central 
regulator of the PI3K/Akt pathway through its dual regulation of both the p110 lipid kinase and 
the corresponding PTEN lipid phosphatase. 
Previous confocal microscopy work involving GFP-PTEN-C124S fusion proteins inspired us 
to assess PTEN subcellular localization in the context of EGF stimulation as well as perform 
some structure/function analyses of PTEN.  The previous work combined with our data is 
helping to build a strong case for the model of PTEN involving the casein kinase 2 
phosphorylation sites regulating open and closed conformations of PTEN.  The data we 
generated suggest that clusters of positive charge in the PASE and C2 domains are important for 
lipid binding, especially to phosphorylated phosphatidylinositol lipids, as well as for plasma 
membrane targeting in response to growth factor stimulation. 
Although the work demonstrated in this thesis does not comprehensively elucidate the 
regulation of PTEN or fully explain the structural nature of the protein, the data presented do 
provide some insight into these two aspects of PTEN.  Greater understanding of all aspects of 
PTEN is critical for the development of therapeutic interventions that will benefit patients with 
cancer.
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APPENDIX I 
Table A1: Normalized values of intensity of lipid spots.  Data was collected using the Odyssey 
imaging system and supplied software.  Values in each replicate were normalized to the C124S 
PI4,5P2 lipid spot values.  
C124S Replicate 1 Replicate 2 Replicate 3 Replicate 4   
PI 0.28 0.21 0.75 0.48   
PI3P 3.76 2.59 3.33 5.60   
PI4P 5.60 4.08 2.46 3.83   
PI5P 2.90 1.74 2.71 3.43   
PI3,4P2 1.84 2.26 1.57 0.86   
PI3,5P2 2.63 2.46 2.59 2.58   
PI4,5P2 1.00 1.00 1.00 1.00   
PI3,4,5P3 1.50 0.80 0.83 0.46   
PA 1.40 1.04 1.36 1.43   
       
STT/AAA Replicate 1 Replicate 2 Replicate 3 Replicate 4  
test 
statistic 
statistically 
significant 
if test 
statistic is 
<0.05 
PI 0.17 0.55 0.57 0.67 0.670 > 0.05 
PI3P 2.80 2.31 2.58 2.15 0.152 > 0.05 
PI4P 2.04 2.85 2.68 2.34 0.148 > 0.05 
PI5P 2.90 2.27 3.01 2.27 0.842 > 0.05 
PI3,4P2 1.92 1.24 1.78 1.15 0.752 > 0.05 
PI3,5P2 2.41 1.36 2.76 1.85 0.195 > 0.05 
PI4,5P2 0.71 1.15 1.52 0.64 0.982 > 0.05 
PI3,4,5P3 1.03 1.20 1.39 0.74 0.467 > 0.05 
PA 0.93 1.26 1.72 1.26 0.945 > 0.05 
       
STT/EEE       
PI 0.03 0.17 0.47 0.29 0.034 < 0.05 
PI3P 2.65 2.79 2.03 1.20 0.189 > 0.05 
PI4P 3.72 2.26 1.67 1.23 0.018 < 0.05 
PI5P 2.05 2.81 1.70 1.05 0.345 > 0.05 
PI3,4P2 1.54 1.75 1.12 0.54 0.004 < 0.05 
PI3,5P2 2.50 2.19 1.71 0.90 0.128 > 0.05 
PI4,5P2 0.90 0.94 0.73 0.35 0.138 > 0.05 
  100 
STT/EEE 
(continued) 
Replicate 1 Replicate 2 Replicate 3 Replicate 4  
test 
statistic 
statistically 
significant 
if test 
statistic is 
<0.05 
PI3,4,5P3 1.31 1.35 0.86 0.38 0.682 > 0.05 
PA 0.87 0.90 0.81 0.49 0.047 < 0.05 
       
PASE 
RKK/AAA 
      
PI 0.02 0.03 0.46 0.14 0.003 < 0.05 
PI3P 0.49 0.63 1.00 0.53 0.020 < 0.05 
PI4P 1.05 1.07 2.27 0.86 0.060 > 0.05 
PI5P 0.47 0.49 1.24 0.40 0.016 < 0.05 
PI3,4P2 0.26 0.39 0.55 0.30 0.023 < 0.05 
PI3,5P2 0.64 0.76 1.12 0.43 0.001 < 0.05 
PI4,5P2 0.16 0.28 0.74 0.12 0.018 < 0.05 
PI3,4,5P3 0.11 0.32 0.67 0.13 0.121 > 0.05 
PA 0.77 0.83 1.53 0.60 0.192 > 0.05 
       
C2-K5A       
PI 0.06 0.00 0.04 0.03 0.042 < 0.05 
PI3P 0.19 0.13 0.32 0.09 0.012 < 0.05 
PI4P 0.15 0.18 0.39 0.09 0.012 < 0.05 
PI5P 0.17 0.16 0.25 0.09 0.006 < 0.05 
PI3,4P2 0.16 0.26 0.44 0.16 0.018 < 0.05 
PI3,5P2 0.36 0.27 0.53 0.25 0.000 < 0.05 
PI4,5P2 0.15 0.07 0.11 0.06 0.000 < 0.05 
PI3,4,5P3 0.18 0.11 0.19 0.20 0.045 < 0.05 
PA 0.11 0.12 0.21 0.11 0.001 < 0.05 
       
C2-K3A       
PI 0.00 0.00 0.00 0.00 0.037 < 0.05 
PI3P 0.45 0.23 0.56 0.09 0.016 < 0.05 
PI4P 0.72 0.37 1.04 0.27 0.018 < 0.05 
PI5P 0.36 0.19 0.48 0.17 0.007 < 0.05 
PI3,4P2 0.04 0.04 0.20 0.00 0.013 < 0.05 
PI3,5P2 0.51 0.14 0.69 0.05 0.000 < 0.05 
PI4,5P2 0.09 0.00 0.13 0.00 0.000 < 0.05 
PI3,4,5P3 0.03 0.00 0.08 0.00 0.027 < 0.05 
PA 0.77 0.28 0.98 0.39 0.015 < 0.05 
       
Y336A       
PI 0.05 0.03 0.34 0.32 0.024 < 0.05 
PI3P 1.21 3.53 1.48 2.38 0.165 > 0.05 
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Y336A 
(continued) 
Replicate 1 Replicate 2 Replicate 3 Replicate 4  
test 
statistic 
statistically 
significant 
if test 
statistic is 
<0.05 
PI4P 1.04 2.63 1.20 3.08 0.103 > 0.05 
PI5P 1.42 3.03 1.42 2.34 0.396 > 0.05 
PI3,4P2 0.86 2.11 0.67 1.46 0.408 > 0.05 
PI3,5P2 1.11 3.20 0.94 2.74 0.413 > 0.05 
PI4,5P2 0.32 1.19 0.50 1.17 0.429 > 0.05 
PI3,4,5P3 0.38 0.81 0.47 0.71 0.377 > 0.05 
PA 0.47 0.54 0.73 1.35 0.054 > 0.05 
       
Y336E       
PI 0.18 0.19 0.09 0.28 0.180 > 0.05 
PI3P 2.35 1.02 1.59 1.16 0.050 > 0.05 
PI4P 1.49 0.86 1.35 0.72 0.020 < 0.05 
PI5P 2.26 1.27 0.76 0.98 0.066 > 0.05 
PI3,4P2 2.01 0.49 3.51 0.81 0.925 > 0.05 
PI3,5P2 3.10 1.07 3.09 1.14 0.460 < 0.05 
PI4,5P2 0.37 0.36 0.85 0.31 0.026 < 0.05 
PI3,4,5P3 0.78 0.41 0.48 0.30 0.041 < 0.05 
PA 1.06 0.81 0.58 0.56 0.040 < 0.05 
 
